{"meta":{"page":1,"per_page":50,"max_per_page":100,"total":261,"total_is_capped":false,"direct_labels_cover":0,"predictions_cover":261,"direct_label_status":"direct model label, unvalidated","prediction_status":"machine_predicted_unvalidated (Codex and Gemma teacher distillation)","score_status":"score_only:v0-immature-baseline (scores rank; they never assert a category)","snapshot":{"source":"OpenAlex, pinned release, all 482 partitions","release":"2026-06-24","frame_built":"2026-07-12"},"query_hash":"6de10d7fb825","filters":{"venue":"Journal for ImmunoTherapy of Cancer"}},"results":[{"id":"W3011642937","doi":"10.1136/jitc-2019-000337","title":"Consensus guidelines for the definition, detection and interpretation of immunogenic cell death","year":2020,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Phagocytosis and Immune Regulation","field":"Immunology and Microbiology","cited_by":1061,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Université de Montréal; Centre Hospitalier de l’Université de Montréal; McMaster University","funders":"National Institute of General Medical Sciences; Associazione Italiana per la Ricerca sul Cancro; Rosetrees Trust; National Institute for Health and Care Research; Compagnia di San Paolo; National Cancer Institute; Cancer Research UK; Weill Cornell Medical College; U.S. Department of Defense","keywords":"Acquired immune system; Immune system; Programmed cell death; Immunogenic cell death; Antigenicity; Immunology; Medicine; Computer science; Biology; Antigen; Immunotherapy; Apoptosis","retraction":null,"screen_n_in":null,"score":{"opus":0.1025040397579904,"gpt":0.3887354754580861,"spread":0.2862314357000957,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005096933,0.0002656718,0.00112618,0.000129477,0.0002515481,0.00002096686,0.0002193696,0.0002852022,0.00004110684],"category_scores_gemma":[0.0001360484,0.0001701753,0.0008279225,0.0001038826,0.0001307163,0.00005358975,0.0000194504,0.0002494863,0.00000108701],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008454228,"about_ca_system_score_gemma":0.0002962727,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004110673,"about_ca_topic_score_gemma":0.000007206106,"domain_scores_codex":[0.9981551,0.000145336,0.001309497,0.000170238,0.00004943182,0.0001703665],"domain_scores_gemma":[0.9964169,0.0007220489,0.001934615,0.0001749791,0.0007406277,0.00001081969],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007355611,0.0000233466,0.000001229864,0.00162996,0.001459957,4.785965e-8,0.0001278464,0.000009040971,0.0354877,0.0000476118,0.0005270339,0.9599507],"study_design_scores_gemma":[0.001849654,0.0005303072,0.00001951367,0.002523416,0.001376298,0.0001027925,0.00006889301,0.00008799353,0.01114853,0.000337617,0.9817734,0.0001816047],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002463493,0.9899409,0.006849386,0.0001601066,0.001448291,0.001106302,0.0002313541,0.000007764966,0.000009490347],"genre_scores_gemma":[0.002364097,0.9965812,0.0004138635,0.0000559721,0.0001130709,0.0002265983,0.00004345256,0.0000471725,0.0001545967],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9812464,"threshold_uncertainty_score":0.6939548,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2952406594","doi":"10.1186/s40425-017-0215-8","title":"Gene expression markers of Tumor Infiltrating Leukocytes","year":2017,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":850,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Women's Health Research Institute","funders":"National Cancer Institute","keywords":"Immune system; Biology; Gene; Gene expression; Immunotherapy; Flow cytometry; Gene expression profiling; Computational biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.02844187749003703,"gpt":0.3487739243891307,"spread":0.3203320468990937,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005717019,0.0001738678,0.0005128306,0.0001208668,0.0003869521,0.00005127561,0.0003152517,0.00007800613,0.0004571834],"category_scores_gemma":[0.00008526674,0.0001315262,0.000472374,0.00005169936,0.0002370704,0.0002327266,0.00001942201,0.0001830314,3.342246e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001183854,"about_ca_system_score_gemma":0.000367892,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002339679,"about_ca_topic_score_gemma":0.00001446133,"domain_scores_codex":[0.9985534,0.00002629201,0.0006921517,0.0001474634,0.0003376875,0.0002430167],"domain_scores_gemma":[0.9976196,0.00007636163,0.001439694,0.0004665478,0.0003313131,0.00006649786],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0161233,0.00007645488,0.01359781,0.0001342189,0.0004806412,0.000003546079,0.0002170366,0.000007828278,0.8709354,0.000006591766,0.001504522,0.09691269],"study_design_scores_gemma":[0.007918112,0.001091918,0.05380713,0.001100937,0.00007359278,0.00009383353,0.0001565724,0.00003515303,0.9142272,0.0001170409,0.02122873,0.0001497185],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9792354,0.01732788,0.0004146554,0.0007570664,0.001108838,0.0004437796,0.00003969749,0.00001103963,0.0006616112],"genre_scores_gemma":[0.9838908,0.006792483,0.007371816,0.0003468186,0.0004478342,0.00004240791,0.000003045489,0.00005134784,0.001053427],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09676297,"threshold_uncertainty_score":0.5363482,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2958648554","doi":"10.1186/s40425-019-0662-5","title":"The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of squamous cell carcinoma of the head and neck (HNSCC)","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":738,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"National Center for Advancing Translational Sciences; University of Texas MD Anderson Cancer Center; National Institute for Health and Care Research; Cancer Research UK; Yale University; Society for Immunotherapy of Cancer; Università degli Studi di Milano; Brigham and Women's Hospital; Yale Cancer Center; Memorial Sloan-Kettering Cancer Center","keywords":"Pembrolizumab; Medicine; Nivolumab; Head and neck squamous-cell carcinoma; Oncology; Internal medicine; Immunotherapy; Cancer; Head and neck cancer; Population","retraction":null,"screen_n_in":null,"score":{"opus":0.02314064955390921,"gpt":0.3334324786407749,"spread":0.3102918290868656,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0009401458,0.0004618526,0.001072432,0.00008809796,0.0004798929,0.00003376973,0.0004783328,0.0001758542,0.000130072],"category_scores_gemma":[0.00001428726,0.000227224,0.002375804,0.0002332727,0.0006357853,0.00005502466,0.00001478138,0.0001960715,1.292382e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005130998,"about_ca_system_score_gemma":0.0009539959,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001583836,"about_ca_topic_score_gemma":0.0002342944,"domain_scores_codex":[0.9969221,0.00008680562,0.001571937,0.0003176359,0.0005697533,0.0005317052],"domain_scores_gemma":[0.9946727,0.001542063,0.002101972,0.0008543659,0.0007753607,0.00005356064],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.100865,0.001232642,0.01176117,0.0006887403,0.006199082,2.346132e-7,0.006431517,0.0002965726,0.605678,0.0001525192,0.003766176,0.2629284],"study_design_scores_gemma":[0.0661817,0.01917744,0.04173076,0.0005986001,0.0005967335,0.00001309389,0.002135157,0.0004246919,0.4815457,0.0002950618,0.386924,0.0003771151],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.790246,0.1989229,0.0001331381,0.003736073,0.001449216,0.004876777,0.0005977848,0.00000641737,0.00003172795],"genre_scores_gemma":[0.8873553,0.1070037,0.0006038584,0.0007928814,0.0002472913,0.0008251852,0.000006618134,0.0001289092,0.003036241],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3831578,"threshold_uncertainty_score":0.9265926,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2905817704","doi":"10.1186/s40425-018-0479-7","title":"High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":571,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Lawson Health Research Institute; Western University","funders":"Canadian Institutes of Health Research","keywords":"Immune system; Immunotherapy; Medicine; Melanoma; Phenotype; Immune checkpoint; Immunology; Cancer research; Cancer; Biology; Internal medicine; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.01551774962185,"gpt":0.3085602037906005,"spread":0.2930424541687505,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001024014,0.0002786619,0.0005848213,0.0002704929,0.0003151981,0.00008164658,0.0001188521,0.0001332356,0.000220305],"category_scores_gemma":[0.0001431583,0.0002213597,0.0001661119,0.0002225332,0.0006226259,0.0001544168,0.00004330808,0.0002440732,0.000001092908],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002200405,"about_ca_system_score_gemma":0.0003591228,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003785404,"about_ca_topic_score_gemma":0.00002525907,"domain_scores_codex":[0.9981561,0.00008035032,0.0007777095,0.000304737,0.0003332834,0.0003477844],"domain_scores_gemma":[0.9985654,0.0002704758,0.0004121381,0.0001971873,0.0003926837,0.0001620878],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.1572043,0.00005530568,0.0003825848,0.00005107161,0.0005520495,0.00001230879,0.001579961,0.000003317602,0.7975258,0.00003760351,0.0001988216,0.04239691],"study_design_scores_gemma":[0.05438302,0.02263518,0.4364368,0.002174249,0.0002304094,0.0008892004,0.00225591,0.0000769024,0.4389621,0.0004139387,0.04068808,0.0008542524],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9759296,0.0179507,0.00006930343,0.004497126,0.0007757843,0.0006848673,0.00004804228,0.00002099542,0.00002358389],"genre_scores_gemma":[0.9924752,0.003902081,0.001808548,0.0005420653,0.0005199033,0.00007279949,0.000003713154,0.00004944169,0.0006263084],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4360542,"threshold_uncertainty_score":0.9026787,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2948662515","doi":"10.1186/s40425-019-0623-z","title":"Final analyses of OPTiM: a randomized phase III trial of talimogene laherparepvec versus granulocyte-macrophage colony-stimulating factor in unresectable stage III–IV melanoma","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immunotherapy and Immune Responses","field":"Immunology and Microbiology","cited_by":438,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Amgen (Canada); Royal Ottawa Mental Health Centre","funders":"National Institute for Health and Care Research; Amgen","keywords":"Medicine; Oncolytic virus; Internal medicine; Melanoma; Confidence interval; Oncology; Hazard ratio; Randomized controlled trial; Cancer; Cancer research","retraction":null,"screen_n_in":null,"score":{"opus":0.05177845107064362,"gpt":0.3877663574224503,"spread":0.3359879063518067,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001726935,0.0004006584,0.002446265,0.0005538135,0.0001603224,0.00002274657,0.0005281803,0.0003527034,0.004294336],"category_scores_gemma":[0.0002529995,0.0003217862,0.001070314,0.0003948523,0.000411356,0.0002560456,0.00004228513,0.0004712004,0.00000381763],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001644073,"about_ca_system_score_gemma":0.000574991,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002262688,"about_ca_topic_score_gemma":0.00006267701,"domain_scores_codex":[0.9959338,0.0008223486,0.002187099,0.0003030399,0.0001977521,0.0005559775],"domain_scores_gemma":[0.9947825,0.002099431,0.002236445,0.0004556108,0.000398624,0.00002736257],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.500325,0.0004392762,0.0001172506,0.00005329077,0.00202644,0.000001829992,0.0007444554,0.000914911,0.4908683,0.00002089162,0.00003223633,0.004456184],"study_design_scores_gemma":[0.55701,0.003909777,0.0001250414,0.0001904849,0.0001287615,0.000007187029,0.0002389946,0.0001423824,0.4360845,0.00001983117,0.001942359,0.0002006585],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9431677,0.0515602,0.0004727539,0.00003710658,0.002311246,0.002041004,0.0002632214,0.00001264814,0.0001340979],"genre_scores_gemma":[0.9898018,0.005408275,0.0002952219,0.0000274424,0.0000530009,0.0001265577,0.00003024683,0.00005522625,0.004202242],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.05668505,"threshold_uncertainty_score":0.9999234,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4206897023","doi":"10.1136/jitc-2021-003777","title":"Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":322,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Spinal Cord Injury BC; University of Calgary; Université de Montréal; McGill University Health Centre","funders":"National Cancer Institute; GlaxoSmithKline","keywords":"Medicine; Cohort; Endometrial cancer; Internal medicine; Microsatellite instability; Interim analysis; Interim; Oncology; Adverse effect; Cancer; Clinical trial; Biology; Microsatellite","retraction":null,"screen_n_in":null,"score":{"opus":0.03358148845380517,"gpt":0.3416970790202096,"spread":0.3081155905664045,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0009664369,0.0004191127,0.001443989,0.0005258995,0.0002894636,0.00003880554,0.0002521416,0.00007145872,0.0007884262],"category_scores_gemma":[0.000263028,0.0002758975,0.0002586705,0.001449191,0.0001581695,0.0002647079,0.0001126839,0.0005096911,1.556541e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001566259,"about_ca_system_score_gemma":0.0007338708,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002653707,"about_ca_topic_score_gemma":0.0008908769,"domain_scores_codex":[0.99595,0.0002865042,0.001530156,0.0006759409,0.001028511,0.0005288204],"domain_scores_gemma":[0.996969,0.0005185975,0.001380112,0.0004688364,0.0005005712,0.0001629126],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.7300828,0.02339357,0.03693705,0.000191321,0.00101693,0.00002558105,0.002748159,0.0001987626,0.014767,0.000001249877,0.00002938182,0.1906082],"study_design_scores_gemma":[0.5854995,0.1685919,0.1400776,0.002078507,0.0009887732,0.00002523761,0.003218872,0.0001045515,0.07855256,0.00004522957,0.01986803,0.0009491899],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9850208,0.005663228,0.00003305863,0.0001565875,0.001346044,0.003964665,0.003768836,0.00002688701,0.00001986282],"genre_scores_gemma":[0.9963903,0.002233248,0.0005480464,0.00007528935,0.0001026324,0.0002959307,0.0001072929,0.00006292974,0.0001842781],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.189659,"threshold_uncertainty_score":0.9999693,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4210910593","doi":"10.1136/jitc-2021-003534","title":"Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":243,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Novelis (Canada)","funders":"High-level Hospital Construction Project of Guangdong Provincial People's Hospital; National Natural Science Foundation of China","keywords":"Immunotherapy; Cancer research; Epidermal growth factor receptor; Tumor microenvironment; CD8; Adenocarcinoma; Immune system; Lung cancer; Biology; Cell; Cytotoxic T cell; Immune checkpoint; Medicine; Cancer; Immunology; Pathology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.01319586278171577,"gpt":0.2763019632293139,"spread":0.2631061004475982,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007588476,0.0003161872,0.001015204,0.0007815657,0.00029108,0.00003320326,0.000357568,0.0000672422,0.004525745],"category_scores_gemma":[0.000007308327,0.0002867868,0.001242554,0.0009188018,0.0001292258,0.0001227691,0.0000320668,0.0005463547,5.200551e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001645902,"about_ca_system_score_gemma":0.0003004188,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003975378,"about_ca_topic_score_gemma":0.00004068819,"domain_scores_codex":[0.9970763,0.000164017,0.001244346,0.0003545193,0.0006358681,0.000524919],"domain_scores_gemma":[0.998512,0.00008222175,0.0008039322,0.000411892,0.00009256498,0.00009737042],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.02189931,0.0009058975,0.02614393,0.0001371722,0.00314689,0.00008215063,0.002494052,0.0005351159,0.9376552,0.000002109018,0.0005559598,0.006442191],"study_design_scores_gemma":[0.05963555,0.006075537,0.285329,0.0005364327,0.003653793,0.0007884009,0.004168834,0.00103766,0.5328885,0.00008013952,0.1047241,0.00108199],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8757089,0.1206564,0.0002636269,0.001452517,0.0006356816,0.0009786271,0.0002074592,0.00001319308,0.00008355091],"genre_scores_gemma":[0.9921131,0.004382261,0.0004521201,0.001006238,0.0001193542,0.0003473966,0.00003128973,0.00007583702,0.001472384],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4047667,"threshold_uncertainty_score":0.9999585,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2612327959","doi":"10.1186/s40425-017-0243-4","title":"Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy","year":2017,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":239,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Ontario Institute for Cancer Research","funders":"","keywords":"Immunotherapy; Immune system; Medicine; Tumor microenvironment; Cancer immunotherapy; Cancer; Immunology; Baseline (sea); Biomarker; Bioinformatics; Oncology; Internal medicine; Biology","retraction":null,"screen_n_in":null,"score":{"opus":0.1856874467329706,"gpt":0.511312647124004,"spread":0.3256252003910334,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.00732536,0.001133406,0.007537948,0.001275781,0.0004413393,0.0001340092,0.001622868,0.001140027,0.001185056],"category_scores_gemma":[0.0004419902,0.0008554443,0.008517291,0.0006504387,0.0006248005,0.0002734196,0.00009931051,0.001399225,0.00001114],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006711661,"about_ca_system_score_gemma":0.002180084,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003548739,"about_ca_topic_score_gemma":0.00002417648,"domain_scores_codex":[0.9882935,0.0005085017,0.008485507,0.0007904231,0.001064112,0.0008579456],"domain_scores_gemma":[0.9874597,0.0007789173,0.008479897,0.001965761,0.0009871126,0.0003286354],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.009432679,0.0004324429,0.0007254312,0.008424779,0.0186948,0.00001726387,0.0001693201,0.000001384779,0.001238445,0.000008607319,0.003399245,0.9574556],"study_design_scores_gemma":[0.01107027,0.001992964,0.0009496042,0.04730251,0.002556729,0.0003118753,0.0000459119,0.000008028744,0.0002202931,0.00004779509,0.9347539,0.0007401335],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0004197063,0.9856511,0.0007681624,0.000471054,0.007969339,0.003919434,0.0005892358,0.00005187278,0.0001601017],"genre_scores_gemma":[0.00009598084,0.991942,0.002159963,0.0003375194,0.000885103,0.0003158194,0.0000923618,0.0003824697,0.003788788],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9567155,"threshold_uncertainty_score":0.999728,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3202872245","doi":"10.1136/jitc-2021-003467","title":"Acute kidney injury in patients treated with immune checkpoint inhibitors","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Toronto; St. Thomas Hospital; University Health Network","funders":"National Institute of Diabetes and Digestive and Kidney Diseases; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Acute kidney injury; Renal function; Internal medicine; Creatinine; Odds ratio; Proportional hazards model; Biopsy; Urology; Gastroenterology","retraction":null,"screen_n_in":null,"score":{"opus":0.008752036805244228,"gpt":0.2927027088432207,"spread":0.2839506720379765,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002792196,0.0002456142,0.0006195684,0.0002289979,0.00009700307,0.00003391327,0.0001177653,0.0001286944,0.0005789162],"category_scores_gemma":[0.00002554281,0.0001806476,0.0004122997,0.0005049664,0.0001063895,0.0001674146,0.00001305243,0.0003072087,9.617399e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004319788,"about_ca_system_score_gemma":0.0008593223,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001796607,"about_ca_topic_score_gemma":0.0000154334,"domain_scores_codex":[0.9981322,0.00004422669,0.0008653062,0.0002242556,0.0003873276,0.0003466872],"domain_scores_gemma":[0.9985408,0.00001963373,0.000477494,0.0002823549,0.0005593964,0.0001203635],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0703733,0.0009173158,0.1900347,0.0001297705,0.002849006,0.00003915483,0.0005832217,0.000003272794,0.623093,0.000006244722,0.003465379,0.1085056],"study_design_scores_gemma":[0.03318033,0.00311795,0.2704534,0.001442786,0.0002064486,0.00008443651,0.00007607198,0.000008673601,0.6188357,0.00003419587,0.07225166,0.000308436],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9918416,0.004872741,0.00003424947,0.00169748,0.0006644105,0.0005441041,0.0001274533,0.00001654567,0.0002014707],"genre_scores_gemma":[0.9797334,0.01323458,0.00102716,0.001996397,0.0003058492,0.0001221311,0.00009639234,0.0001231311,0.003360976],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1081971,"threshold_uncertainty_score":0.7366597,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3042095160","doi":"10.1136/jitc-2020-000891","title":"Survival outcomes and independent response assessment with nivolumab plus ipilimumab versus sunitinib in patients with advanced renal cell carcinoma: 42-month follow-up of a randomized phase 3 clinical trial","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":225,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"BC Cancer Agency","funders":"Bristol-Myers Squibb; Ono Pharmaceutical; National Cancer Institute; National Institutes of Health; Memorial Sloan-Kettering Cancer Center; University of Texas MD Anderson Cancer Center","keywords":"Nivolumab; Medicine; Sunitinib; Ipilimumab; Renal cell carcinoma; Internal medicine; Randomized controlled trial; Oncology; Clinical trial; Immunotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.04926157250532811,"gpt":0.3799343260798284,"spread":0.3306727535745003,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001693459,0.0003654546,0.002366127,0.0001989843,0.00007730006,0.00002481262,0.0001571956,0.0001229104,0.00007246981],"category_scores_gemma":[0.000200357,0.0002295427,0.0005433786,0.0001932589,0.0002388305,0.0001508588,0.0000266036,0.0004844054,1.597163e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004496229,"about_ca_system_score_gemma":0.001463207,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001382806,"about_ca_topic_score_gemma":0.00009467603,"domain_scores_codex":[0.9961106,0.0006643534,0.00155824,0.0003654813,0.0009611414,0.0003402168],"domain_scores_gemma":[0.9963655,0.001266854,0.001308708,0.0002844514,0.0005308514,0.0002436158],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9422849,0.00138875,0.04677108,0.00008493234,0.001353931,0.00004721269,0.0008391219,0.00007328096,0.0009991027,0.000004025902,0.00001726354,0.006136346],"study_design_scores_gemma":[0.8249253,0.05101782,0.1209302,0.000166811,0.0006823579,0.000003937325,0.0003408389,0.00008956106,0.001486466,0.000004007928,0.0001564346,0.0001962634],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9934313,0.001521176,0.0002766148,0.0004680229,0.0006460003,0.003502117,0.00007404187,0.000009257091,0.00007142164],"genre_scores_gemma":[0.9973435,0.0003557891,0.001687081,0.00008554057,0.0001056426,0.0001773615,0.00002132571,0.00006477988,0.0001589491],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1173597,"threshold_uncertainty_score":0.936048,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3190341154","doi":"10.1186/s40425-015-0078-9","title":"Pembrolizumab","year":2015,"lang":"id","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":222,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"Canadian Institutes of Health Research","keywords":"Pembrolizumab; Ipilimumab; Medicine; Melanoma; Oncology; Internal medicine; Lung cancer; Nivolumab; Cancer; Immunotherapy; Cancer research","retraction":null,"screen_n_in":null,"score":{"opus":0.06837773108908334,"gpt":0.4185399310356333,"spread":0.35016219994655,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.002713908,0.00120316,0.004977674,0.0007121284,0.0003738242,0.0001524551,0.001035559,0.0009673962,0.004153819],"category_scores_gemma":[0.00009385208,0.000905073,0.00436433,0.0007122168,0.0004689783,0.0002620774,0.00004952221,0.001439467,0.00004146812],"about_ca_system_candidate":true,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002357351,"about_ca_system_score_gemma":0.008113945,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002046062,"about_ca_topic_score_gemma":0.00002491694,"domain_scores_codex":[0.9931641,0.0003151261,0.003393219,0.0006206618,0.001399392,0.001107535],"domain_scores_gemma":[0.9922196,0.0003083232,0.004176041,0.0009433979,0.001918402,0.0004342696],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01777302,0.0003565191,0.00003654614,0.009335047,0.009563198,0.00001839262,0.0005486885,0.000003839438,0.0009640816,0.00002974195,0.05254443,0.9088265],"study_design_scores_gemma":[0.01926395,0.003299314,0.00006934421,0.02911054,0.003159333,0.0007541437,0.0001431547,0.000008605199,0.0002878774,0.0001494502,0.942897,0.0008573364],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0002517563,0.9819048,0.0002007825,0.0006267632,0.0122392,0.002833716,0.0004822625,0.0000308851,0.001429855],"genre_scores_gemma":[0.0000670943,0.9631194,0.000337382,0.0006104847,0.004131761,0.0003642248,0.00007079106,0.0003613722,0.03093753],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9079692,"threshold_uncertainty_score":0.99934,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2060260809","doi":"10.1186/s40425-015-0055-3","title":"Survival with AGS-003, an autologous dendritic cell–based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":214,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McGill University; Jewish General Hospital; Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Sunitinib; Renal cell carcinoma; Immunotherapy; Internal medicine; Clinical endpoint; Oncology; Progression-free survival; Phases of clinical research; Surgery; Urology; Gastroenterology; Overall survival; Clinical trial; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.02350134221702204,"gpt":0.3124838008042494,"spread":0.2889824585872273,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001023635,0.0004988675,0.0009981671,0.0005928106,0.0001483569,0.00005650419,0.0002516189,0.0001157294,0.00002633144],"category_scores_gemma":[0.00002253124,0.0003371842,0.0001055638,0.0006250427,0.0001473194,0.0003955691,0.00001029526,0.0005983323,6.455901e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001025304,"about_ca_system_score_gemma":0.001288627,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002040136,"about_ca_topic_score_gemma":0.002243092,"domain_scores_codex":[0.9964183,0.0004484153,0.001001682,0.000499777,0.001030838,0.0006009704],"domain_scores_gemma":[0.9970244,0.000181408,0.001047076,0.0005706594,0.0009390875,0.0002373614],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2658976,0.01912354,0.6802716,0.0001111418,0.0003425753,0.0003756452,0.004909988,0.00914975,0.004592494,0.000002294743,0.00003538918,0.01518799],"study_design_scores_gemma":[0.3744212,0.1166994,0.4792919,0.0005085928,0.0002675345,0.00003914521,0.003052504,0.0004827555,0.02428083,0.00002709402,0.0003882447,0.0005408934],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.993957,0.001980745,0.0003435468,0.00009852002,0.0001737055,0.00305674,0.0001182879,0.00002483103,0.0002465967],"genre_scores_gemma":[0.9964316,0.0001378809,0.002598932,0.00006827909,0.00004144094,0.000266684,0.000125568,0.0001329918,0.0001965865],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2009798,"threshold_uncertainty_score":0.999908,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4205273215","doi":"10.1136/jitc-2021-003497","title":"Neoadjuvant programmed cell death 1 blockade combined with chemotherapy for resectable esophageal squamous cell carcinoma","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Esophageal Cancer Research and Treatment","field":"Medicine","cited_by":214,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; St. Joseph’s Healthcare Hamilton; University of Manitoba","funders":"","keywords":"Blockade; Esophageal squamous cell carcinoma; Chemotherapy; Basal cell; Cell; Neoadjuvant therapy; Programmed cell death","retraction":null,"screen_n_in":null,"score":{"opus":0.01985469544806639,"gpt":0.3174916672448145,"spread":0.2976369717967481,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000508029,0.0003174876,0.0006796337,0.000221504,0.0006291719,0.00005201813,0.000302927,0.00006666492,0.000774949],"category_scores_gemma":[0.00000936604,0.000235954,0.0004330094,0.000275249,0.00008075519,0.00009245326,0.00002851586,0.0004838378,6.551666e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0008126477,"about_ca_system_score_gemma":0.001249584,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004070332,"about_ca_topic_score_gemma":0.00003657155,"domain_scores_codex":[0.9974561,0.00007055938,0.0005216958,0.0003416368,0.0008242794,0.0007857308],"domain_scores_gemma":[0.9983577,0.0001580207,0.0004365864,0.000358714,0.0004281449,0.0002608996],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.5162463,0.01327019,0.1609335,0.002959342,0.002757654,0.0007616606,0.005847645,0.001921268,0.1393543,0.000227415,0.02474054,0.1309802],"study_design_scores_gemma":[0.1742921,0.1159282,0.0173591,0.0001137338,0.0005191364,0.0004166157,0.0008661304,0.0009697431,0.5980983,0.0007766407,0.08997574,0.0006844406],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9244317,0.0666513,0.0005981296,0.002535029,0.0004120703,0.004793223,0.0002576097,0.00004232058,0.0002786653],"genre_scores_gemma":[0.983456,0.0007211199,0.00387969,0.000536663,0.0003158492,0.002503397,0.00004741898,0.0001388924,0.008400979],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.458744,"threshold_uncertainty_score":0.9621924,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2800568511","doi":"10.1186/s40425-018-0328-8","title":"Distinct predictive biomarker candidates for response to anti-CTLA-4 and anti-PD-1 immunotherapy in melanoma patients","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Infection and Immunity","funders":"National Institutes of Health; National Cancer Institute; Melanoma Research Alliance","keywords":"Medicine; Immunotherapy; Melanoma; CTLA-4; Biomarker; Blockade; Oncology; Ipilimumab; Immune checkpoint; Predictive value; Immunology; Immune system; Internal medicine; T cell; Cancer research; Biology; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.01553689290058551,"gpt":0.3295910235753453,"spread":0.3140541306747597,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.001220328,0.0003673335,0.0008114344,0.0005492981,0.0002840548,0.00006872384,0.000236036,0.0001818831,0.0002243488],"category_scores_gemma":[0.0001359674,0.0002929401,0.0003331938,0.0004373103,0.0003290704,0.0002131161,0.00002459281,0.0001782121,0.000001390689],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003993973,"about_ca_system_score_gemma":0.0004142226,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003209489,"about_ca_topic_score_gemma":0.0001196649,"domain_scores_codex":[0.9975981,0.000113297,0.0009501089,0.0004030844,0.0003698143,0.0005655932],"domain_scores_gemma":[0.9980022,0.0003248504,0.0004930537,0.0003355693,0.0006914816,0.0001528191],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.2184354,0.0003964864,0.1733625,0.00009518983,0.00114332,0.000003316794,0.001982364,0.000001762992,0.4889036,0.000004453867,0.003288168,0.1123835],"study_design_scores_gemma":[0.02627201,0.00655556,0.7948139,0.0006887902,0.00007946687,0.0000362727,0.0001457312,0.0001211385,0.05283992,0.0001058521,0.1179833,0.0003581094],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9855255,0.007605517,0.001074757,0.001853559,0.001219246,0.002176833,0.0004535389,0.00002310046,0.00006792802],"genre_scores_gemma":[0.9934679,0.003005828,0.001143181,0.001069628,0.0003316757,0.0002792783,0.00002254357,0.0001043947,0.0005755914],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6214514,"threshold_uncertainty_score":0.9999523,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3037575240","doi":"10.1136/jitc-2019-000467","title":"Acute kidney injury associated with immune checkpoint inhibitor therapy: incidence, risk factors and outcomes","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":193,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University Health Network","funders":"University Health Network","keywords":"Medicine; Acute kidney injury; Internal medicine; Creatinine; Incidence (geometry); Kidney disease; Adverse effect; Cancer; Gastroenterology; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.01782328958163311,"gpt":0.3066846269328215,"spread":0.2888613373511884,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004661741,0.0003987457,0.0009761348,0.0001531319,0.0002717244,0.00006967401,0.0001970471,0.0001760431,0.0003396232],"category_scores_gemma":[0.0001480061,0.0002452076,0.0005404171,0.000358676,0.0002492254,0.0002584256,0.0000217353,0.0005041455,5.352261e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002031124,"about_ca_system_score_gemma":0.0005591752,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002692829,"about_ca_topic_score_gemma":0.00001090157,"domain_scores_codex":[0.9978923,0.00007512316,0.0008532812,0.000288952,0.0005071212,0.0003832879],"domain_scores_gemma":[0.9980049,0.0001163722,0.001056495,0.000224338,0.0003151848,0.0002827393],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.04223474,0.0002539573,0.4402691,0.00006907555,0.009997102,0.00001025912,0.003373517,0.000002627735,0.4601774,0.000005178592,0.002749557,0.04085747],"study_design_scores_gemma":[0.02987778,0.008288154,0.6315941,0.0008331463,0.0006314708,0.00004421207,0.000397201,0.00006659229,0.2790971,0.00009318312,0.04844824,0.0006288601],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9832516,0.009484472,0.0001679668,0.005257677,0.000514854,0.0008211364,0.000416704,0.00004945982,0.00003616909],"genre_scores_gemma":[0.9600559,0.03525358,0.0004091666,0.003504047,0.0002377463,0.00005819033,0.00002504743,0.0001029988,0.0003532787],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.191325,"threshold_uncertainty_score":0.9999276,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2888941300","doi":"10.1186/s40425-018-0398-7","title":"Combining surgery and immunotherapy: turning an immunosuppressive effect into a therapeutic opportunity","year":2018,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer, Stress, Anesthesia, and Immune Response","field":"Medicine","cited_by":189,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier Universitaire de Sherbrooke; Université de Sherbrooke","funders":"Natural Sciences and Engineering Research Council of Canada; Cancer Research Society","keywords":"Medicine; Immunosuppression; Immunotherapy; Perioperative; Cancer; Immune system; Surgical stress; Cancer immunotherapy; Intensive care medicine; Immunology; Bioinformatics; Surgery; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.0573483934805771,"gpt":0.3991111887728901,"spread":0.341762795292313,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.002719744,0.001095765,0.005226797,0.0008790283,0.0006677886,0.0002207669,0.0005380426,0.0006868003,0.0004212653],"category_scores_gemma":[0.0002187853,0.0008068527,0.002349365,0.000391484,0.0006351332,0.0004185384,0.00005018018,0.001272994,0.000002814103],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00051485,"about_ca_system_score_gemma":0.003017372,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002901795,"about_ca_topic_score_gemma":0.00001340735,"domain_scores_codex":[0.9948186,0.001016353,0.002116335,0.0006261579,0.0006381139,0.0007844812],"domain_scores_gemma":[0.993146,0.002083416,0.002881645,0.000970363,0.0005779822,0.0003406056],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.007135829,0.0001932048,0.000129703,0.009437033,0.00424814,0.00003283187,0.001267444,4.85348e-7,0.001055441,0.000005301498,0.000808424,0.9756862],"study_design_scores_gemma":[0.003890871,0.003382008,0.0002817668,0.03595046,0.002001374,0.002290585,0.0001503539,0.00001276666,0.0003727649,0.00008759194,0.9507921,0.0007872958],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.01028843,0.9852351,0.00007514958,0.0001116258,0.002202669,0.001936779,0.00005070247,0.00005830346,0.00004126884],"genre_scores_gemma":[0.0004606447,0.9956501,0.0002052081,0.0003221036,0.001701955,0.0004641836,0.00008209744,0.0003679143,0.0007457984],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9748989,"threshold_uncertainty_score":0.9994382,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2973724679","doi":"10.1186/s40425-019-0734-6","title":"Immunosuppression by monocytic myeloid-derived suppressor cells in patients with pancreatic ductal carcinoma is orchestrated by STAT3","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":187,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University Hospital Foundation","funders":"Qatar National Research Fund; Istituto Oncologico Veneto; Fondazione Italiana per la Ricerca sul Cancro; Università degli Studi di Verona; Università Cattolica del Sacro Cuore; Università degli Studi di Padova; Cancer Research Institute; Fondazione Italiana per la ricerca sulle Malattie del Pancreas; EuroNanoMed III; Associazione Italiana per la Ricerca sul Cancro; Agence Nationale de la Recherche","keywords":"CD14; Myeloid-derived Suppressor Cell; Immunosuppression; Medicine; Immune system; Cancer research; Myeloid; Flow cytometry; STAT3; Immunology; CD16; Suppressor; Biology; Internal medicine; Cancer; Apoptosis","retraction":null,"screen_n_in":null,"score":{"opus":0.005649180257663867,"gpt":0.2396133105434502,"spread":0.2339641302857864,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0002573722,0.0004220208,0.0007925736,0.0001695225,0.0001613471,0.00004232323,0.0005373301,0.0003291475,0.002709267],"category_scores_gemma":[0.000009283452,0.000331097,0.0001926878,0.0001997642,0.0002282331,0.0003286586,0.00003997569,0.0006401743,0.00003056627],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004069838,"about_ca_system_score_gemma":0.0003159265,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005698148,"about_ca_topic_score_gemma":0.000006599185,"domain_scores_codex":[0.9976934,0.0001884015,0.0008555437,0.0003983568,0.0001673449,0.0006969441],"domain_scores_gemma":[0.9982671,0.0001702836,0.0007555269,0.0004610645,0.0003108315,0.00003515888],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.007990941,0.0003265888,0.04945101,0.0000807255,0.0006531741,0.000001001241,0.001127531,0.00005024062,0.9186215,0.000001302124,0.01951132,0.002184606],"study_design_scores_gemma":[0.02078339,0.001616808,0.03493682,0.0003147495,0.00008178643,0.000009570052,0.0002592696,0.00001256224,0.9150389,0.00003046865,0.02645629,0.0004593978],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9625801,0.03369745,0.0000504197,0.0001300598,0.001791315,0.001089451,0.0005795302,0.0000178742,0.00006374952],"genre_scores_gemma":[0.9916223,0.002251171,0.0001372619,0.0002377141,0.00002238629,0.00009897552,0.0001607753,0.0001029757,0.005366414],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.03144628,"threshold_uncertainty_score":0.9999141,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2895870246","doi":"10.1186/s40425-018-0420-0","title":"Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Renal cell carcinoma treatment","field":"Medicine","cited_by":180,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Alberta; University of Calgary; BC Cancer Agency","funders":"National Cancer Institute; Bristol-Myers Squibb","keywords":"Medicine; Pazopanib; Nivolumab; Sunitinib; Renal cell carcinoma; Tolerability; Discontinuation; Adverse effect; Internal medicine; Clinical endpoint; Oncology; Peripheral edema; Urology; Clinical trial; Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.02981774737536692,"gpt":0.3328356411832563,"spread":0.3030178938078893,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006439441,0.0001827281,0.0005709768,0.000203161,0.00008385169,0.0000132206,0.0001160807,0.00003162967,0.0001386463],"category_scores_gemma":[0.00003553875,0.00009026068,0.00007043352,0.0003211861,0.0001578882,0.000105786,0.00001340064,0.0001949966,2.635915e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002493974,"about_ca_system_score_gemma":0.0003817083,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004481237,"about_ca_topic_score_gemma":0.001578339,"domain_scores_codex":[0.998467,0.0001335167,0.0006830574,0.0001668969,0.0003260175,0.0002235471],"domain_scores_gemma":[0.9986911,0.0002662129,0.0004902993,0.0002186604,0.0002876436,0.00004613096],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"observational","study_design_scores_codex":[0.5002815,0.007814197,0.1878711,0.0006764894,0.001264443,0.000280147,0.02953402,0.0002951683,0.1132658,0.00003771272,0.00009890672,0.1585805],"study_design_scores_gemma":[0.09194931,0.02702075,0.8177083,0.0005511792,0.0002654458,0.000149814,0.003605979,0.0001329122,0.05777229,0.00004098737,0.0006383928,0.0001646195],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950663,0.002599109,0.00008110273,0.0002643559,0.00008855562,0.001798527,0.00001242053,0.000003738238,0.00008581805],"genre_scores_gemma":[0.997632,0.0007796071,0.0007122122,0.00005524634,0.000041316,0.00007361278,0.00000263143,0.0000341558,0.0006692333],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6298372,"threshold_uncertainty_score":0.3680724,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3011282656","doi":"10.1136/jitc-2019-000282","title":"Potent STING activation stimulates immunogenic cell death to enhance antitumor immunity in neuroblastoma","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"interferon and immune responses","field":"Immunology and Microbiology","cited_by":175,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Vanderbilt Institute of Chemical Biology, School of Medicine, Vanderbilt University; Division of Chemical, Bioengineering, Environmental, and Transport Systems; National Institute of Diabetes and Digestive and Kidney Diseases; American Cancer Society; Vanderbilt University Medical Center; Vanderbilt University; Stand Up To Cancer; National Cancer Institute; Entertainment Industry Foundation; National Science Foundation; Canadian Institutes of Health Research; Alex's Lemonade Stand Foundation for Childhood Cancer; Vanderbilt Digestive Diseases Research Center, Vanderbilt University Medical Center; American Association for Cancer Research; National Institutes of Health","keywords":"Sting; Stimulator of interferon genes; Cancer research; Neuroblastoma; Immunogenic cell death; Immunotherapy; CD8; Programmed cell death; T cell; Cancer immunotherapy; Medicine; Apoptosis; Blockade; Interferon; Immune checkpoint; Immunogenicity; Immune system; Cell cycle checkpoint; Immunology; Biology; Cell cycle; Cell culture; Cancer; Innate immune system; Receptor; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.0229599501272848,"gpt":0.3284229721530053,"spread":0.3054630220257205,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003377812,0.0002326686,0.0004562146,0.0001977691,0.0002211475,0.00003370401,0.0004137858,0.0001250429,0.0003829839],"category_scores_gemma":[0.0001361057,0.0002089204,0.0002358112,0.0002327265,0.0000550893,0.0001972713,0.00005509885,0.000519891,0.00002593555],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001329679,"about_ca_system_score_gemma":0.0001859339,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002348366,"about_ca_topic_score_gemma":0.00001039624,"domain_scores_codex":[0.9983838,0.0002118882,0.0007099643,0.0002160715,0.00006934631,0.0004089655],"domain_scores_gemma":[0.9989314,0.0002120276,0.0004120912,0.0001909558,0.0002192623,0.00003426134],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00847418,0.0001301438,0.0005810869,0.00003872978,0.0001577564,0.000001655238,0.001611697,0.000948207,0.9661118,0.00001143602,0.0003818671,0.02155145],"study_design_scores_gemma":[0.002309053,0.001600417,0.01306683,0.0002168523,0.00001803181,0.00001964985,0.0003053086,0.00006274321,0.9652801,0.00002474476,0.01687843,0.0002179067],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860722,0.009380697,0.001971842,0.001252706,0.0007407696,0.0004624165,0.00002567301,0.00002424661,0.00006939461],"genre_scores_gemma":[0.9965352,0.001208741,0.0003417479,0.001071297,0.00005687304,0.0000359508,0.000006872214,0.00004185212,0.0007014303],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.02133355,"threshold_uncertainty_score":0.8519526,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2886177168","doi":"10.1186/s40425-018-0381-3","title":"White paper on microbial anti-cancer therapy and prevention","year":2018,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Research and Treatments","field":"Biochemistry, Genetics and Molecular Biology","cited_by":167,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Innovative Targeting Solutions (Canada)","funders":"National Cancer Institute","keywords":"Cancer therapy; Oncolytic virus; Medicine; Cancer; Cancer treatment; Commercialization; Intensive care medicine; Business; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.0546215324629758,"gpt":0.4213625898970199,"spread":0.3667410574340441,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002133533,0.0003193059,0.0007162812,0.0001062295,0.0001429002,0.00005920684,0.0002245892,0.0002476354,0.0002757547],"category_scores_gemma":[0.000006020413,0.0002261993,0.0006466466,0.00007078108,0.0001104639,0.000009156854,0.00002544113,0.0001815489,0.000001722428],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008442285,"about_ca_system_score_gemma":0.0005079824,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00004912573,"about_ca_topic_score_gemma":0.00007822342,"domain_scores_codex":[0.9986952,0.00008927815,0.000433108,0.0003158952,0.0001781289,0.0002883821],"domain_scores_gemma":[0.9989804,0.00001414505,0.0005117076,0.0002509169,0.0001720424,0.00007080819],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0008326744,0.00009686092,0.0000385793,0.0006821756,0.001931656,5.331902e-7,0.00002158522,6.888562e-7,0.005511736,0.000001879791,0.01064061,0.980241],"study_design_scores_gemma":[0.002225228,0.001604636,0.00004767432,0.002625836,0.0001112854,0.00001984723,0.000002801385,1.212147e-7,0.003532333,0.00002957595,0.9895808,0.0002198294],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.003661614,0.9945114,0.0000301785,0.00006340768,0.0005579448,0.0008182956,0.0003043503,0.000002946632,0.00004991019],"genre_scores_gemma":[0.00003292176,0.9935355,0.0001355565,0.0001397407,0.001181259,0.0002848073,0.00007298443,0.00007916284,0.0045381],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9800212,"threshold_uncertainty_score":0.9224141,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4214685750","doi":"10.1136/jitc-2021-003776","title":"Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":156,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Cancer Institute; Novartis Pharmaceuticals Corporation; American Society of Clinical Oncology; Novartis","keywords":"Medicine; Adverse effect; Dosing; Internal medicine; Oncology; Cancer; Gastroenterology","retraction":null,"screen_n_in":null,"score":{"opus":0.01189213994870178,"gpt":0.3023932276310027,"spread":0.290501087682301,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.000456055,0.0002491513,0.0006628272,0.0002270644,0.0004427375,0.00001478534,0.0003304332,0.00004870632,0.0003684645],"category_scores_gemma":[0.00001600161,0.0001625462,0.000290775,0.0006054202,0.0001437496,0.0001556206,0.00006022253,0.0003693914,8.436162e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000406819,"about_ca_system_score_gemma":0.0004337337,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001903544,"about_ca_topic_score_gemma":0.0001268162,"domain_scores_codex":[0.9975748,0.0001156353,0.0008761121,0.0002386697,0.0008544578,0.000340294],"domain_scores_gemma":[0.9983341,0.00004606361,0.0008452661,0.0004224641,0.0003062267,0.00004589012],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.2335372,0.03178137,0.2862551,0.0002692523,0.002903864,0.00001751521,0.0166974,0.001333903,0.1922294,0.00001553534,0.002115649,0.2328438],"study_design_scores_gemma":[0.2995303,0.08939952,0.4927825,0.0009764119,0.0003574913,0.00005089568,0.007719755,0.00004265583,0.05021892,0.00005319942,0.05823958,0.0006287693],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9896597,0.00664553,0.000008952424,0.0004335452,0.001075435,0.002009497,0.0001298225,0.00001006132,0.00002748114],"genre_scores_gemma":[0.9981884,0.0005757145,0.00008424517,0.0003382035,0.00007594601,0.0002417705,0.000007458222,0.00005662845,0.0004316474],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2322151,"threshold_uncertainty_score":0.6628442,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2981595408","doi":"10.1186/s40425-019-0762-2","title":"Systemic and local immunity following adoptive transfer of NY-ESO-1 SPEAR T cells in synovial sarcoma","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":145,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Pediatric Oncology Group","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; EMD Serono; Eisai; Servier; Amgen; Pfizer; Daiichi Sankyo Europe; Eli Lilly and Company; Eurostars; GlaxoSmithKline","keywords":"Medicine; T cell; Immunology; Fludarabine; Tumor microenvironment; Progressive disease; Synovial sarcoma; Cytotoxic T cell; Immune system; Cancer research; Internal medicine; Pathology; Sarcoma; Biology; Disease; Chemotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.01853585997131978,"gpt":0.3255511113769634,"spread":0.3070152514056436,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0009969873,0.000185781,0.0007887727,0.0002986505,0.00005104053,0.00001686729,0.0001808412,0.0001387396,0.0009478442],"category_scores_gemma":[0.00001172552,0.0001544457,0.0003956775,0.0002205867,0.0001338428,0.0001284304,0.00001597374,0.0005375503,0.000001827049],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003106876,"about_ca_system_score_gemma":0.0003603352,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0005365323,"about_ca_topic_score_gemma":0.00005067927,"domain_scores_codex":[0.9981915,0.0001219285,0.0006834003,0.0001705383,0.0004921919,0.0003404333],"domain_scores_gemma":[0.9990917,0.000207721,0.0001456732,0.0002575644,0.0002128303,0.0000845353],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00864249,0.0001740974,0.01109008,0.0003854081,0.00059718,0.00001224222,0.002214938,0.0001013365,0.9219583,0.00001925384,0.00003717182,0.05476748],"study_design_scores_gemma":[0.04942866,0.007312724,0.03321019,0.005429511,0.0002407585,0.0003961446,0.005008857,0.0009043004,0.8850603,0.0002203974,0.01221785,0.0005703816],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9806718,0.01659469,0.0007251451,0.0001291099,0.0005753594,0.001004399,0.00002559863,0.000006209184,0.0002677269],"genre_scores_gemma":[0.9928043,0.005100977,0.0001912221,0.0000760481,0.0001100017,0.00001932932,0.000001812484,0.00005342207,0.001642873],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0541971,"threshold_uncertainty_score":0.9999654,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3006887831","doi":"10.1136/jitc-2019-000186","title":"On the mechanism of anti-CD39 immune checkpoint therapy","year":2020,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Adenosine and Purinergic Signaling","field":"Biochemistry, Genetics and Molecular Biology","cited_by":140,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research; Institute of Cancer Research; Terry Fox Research Institute","keywords":"Adenosinergic; Medicine; Immunotherapy; Adenosine; Mechanism of action; Cancer immunotherapy; Regulator; Adenosine receptor; Immune system; Targeted therapy; Pharmacology; Immunology; Cancer; Receptor; Cancer research; Biology; Internal medicine; In vitro; Gene","retraction":null,"screen_n_in":null,"score":{"opus":0.03803198016739658,"gpt":0.3450691634505271,"spread":0.3070371832831305,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004284298,0.0003336005,0.001107664,0.00006704464,0.0001048159,0.00002031465,0.0005823286,0.000247431,0.0002059903],"category_scores_gemma":[0.00003689156,0.0001924335,0.001390535,0.0001170411,0.00006678468,0.000002949171,0.00003310698,0.0003196828,0.000001107011],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00002666413,"about_ca_system_score_gemma":0.0004175417,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001468689,"about_ca_topic_score_gemma":3.021019e-7,"domain_scores_codex":[0.9983793,0.0001113487,0.0008771506,0.000210814,0.0002188383,0.0002025382],"domain_scores_gemma":[0.9980353,0.00008565805,0.001321117,0.0003492608,0.0001710597,0.00003767914],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0007244675,0.0001502323,7.683814e-7,0.001566654,0.004211859,0.000003249953,0.0001378618,0.00003025127,0.1210985,0.00154025,0.007038045,0.8634979],"study_design_scores_gemma":[0.0007392471,0.000794691,6.595757e-7,0.001962021,0.0001260852,0.00002850341,0.00001575256,0.000002389085,0.06157186,0.0004556498,0.9341021,0.0002011043],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0006649242,0.9970275,0.000796983,0.0002368156,0.0005573774,0.000572032,0.00007878713,0.00000300265,0.00006263267],"genre_scores_gemma":[0.0007070097,0.9977495,0.0001101623,0.0002116409,0.000681561,0.00007935369,0.00002143286,0.00008417949,0.000355128],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.927064,"threshold_uncertainty_score":0.784721,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3134221665","doi":"10.1136/jitc-2020-001901","title":"Considerations for treatment duration in responders to immune checkpoint inhibitors","year":2021,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":134,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pediatric Oncology Group","funders":"National Cancer Institute; Society for Immunotherapy of Cancer","keywords":"Medicine; Immunotherapy; Clinical trial; Limiting; Oncology; Cancer; Internal medicine; Intensive care medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.08771796083704402,"gpt":0.4250182670291007,"spread":0.3373003061920567,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0008281486,0.0004726883,0.002486107,0.0006864109,0.0001830871,0.00007846495,0.0001094642,0.0003232147,0.0003658918],"category_scores_gemma":[0.000172692,0.0003603957,0.002266562,0.0004352259,0.00006316089,0.0001005825,0.00001019807,0.0002111876,0.000001083012],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002066978,"about_ca_system_score_gemma":0.003242139,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001751003,"about_ca_topic_score_gemma":0.0002438067,"domain_scores_codex":[0.9966056,0.0001205822,0.002265585,0.0003559512,0.0002749844,0.0003773316],"domain_scores_gemma":[0.9974738,0.0004951104,0.001117365,0.0003743557,0.0004371635,0.0001022413],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.003689289,0.000281122,0.000005067762,0.002451339,0.00237141,0.00001051503,0.0007415548,0.00001006796,0.006335633,0.00003375335,0.002044293,0.982026],"study_design_scores_gemma":[0.007232773,0.001862633,0.00002729976,0.01786589,0.0007223974,0.0001943261,0.0001655598,0.000003674984,0.003314499,0.00008378379,0.9681942,0.0003329303],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0003894802,0.9911799,0.0002670087,0.001839444,0.001701503,0.00433374,0.0002472847,0.00001287782,0.00002871276],"genre_scores_gemma":[0.00005234488,0.9925337,0.002574308,0.000269063,0.000583881,0.001893728,0.00009351979,0.0001175746,0.001881893],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.981693,"threshold_uncertainty_score":0.9998848,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3034105569","doi":"10.1136/jitc-2019-000266","title":"Nectin4 is a novel TIGIT ligand which combines checkpoint inhibition and tumor specificity","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":123,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Israel Science Foundation; Hebrew University of Jerusalem; Centre in Green Chemistry and Catalysis; Israel Cancer Research Fund","keywords":"TIGIT; Cancer research; Medicine; Computational biology; Computer science; Internal medicine; Biology; Immunotherapy; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.02615766639445402,"gpt":0.2801342962558834,"spread":0.2539766298614293,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0001621285,0.0001510529,0.0002990603,0.00007248548,0.0002219295,0.00004130165,0.00007531491,0.0001007194,0.001281662],"category_scores_gemma":[0.00004634233,0.0001282714,0.0001473619,0.0001217955,0.00007013768,0.0002021483,0.00001621594,0.0003289956,0.00001692601],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00004720574,"about_ca_system_score_gemma":0.0000685755,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00007185635,"about_ca_topic_score_gemma":0.00001038094,"domain_scores_codex":[0.9991265,0.00002911065,0.0004531198,0.0001657872,0.00004594717,0.0001795163],"domain_scores_gemma":[0.9991252,0.00005461966,0.000392688,0.00008561461,0.0003166792,0.00002519053],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002440444,0.00009142907,0.0005160551,0.00003469473,0.0002625014,2.546116e-7,0.001164875,0.000006463745,0.9725785,0.00006373993,0.0188239,0.00401717],"study_design_scores_gemma":[0.00367545,0.0006026565,0.002209797,0.00007896831,0.00002800046,0.00009342952,0.0003233979,0.00003551145,0.6682516,0.00007336326,0.324504,0.0001238431],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9782988,0.01017982,0.001959677,0.005719346,0.003227461,0.0002776692,0.00002780002,0.00002610257,0.0002833638],"genre_scores_gemma":[0.9916585,0.002597615,0.0001145143,0.002853059,0.0002201602,0.00002123201,0.00001417181,0.0000296969,0.00249105],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3056801,"threshold_uncertainty_score":0.9996313,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3091948129","doi":"10.1136/jitc-2020-001006","title":"Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":118,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University Health Network","funders":"Amgen","keywords":"Pembrolizumab; Medicine; Rash; Maculopapular rash; Internal medicine; Adverse effect; Refractory (planetary science); Gastroenterology; Lung cancer; Oncology; Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.01364674565156922,"gpt":0.3253575315053835,"spread":0.3117107858538143,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002335357,0.0002259359,0.0007686203,0.0002075167,0.00006799072,0.000016744,0.0001158364,0.00008385227,0.00009385873],"category_scores_gemma":[0.00003406167,0.000153184,0.00009164485,0.0004083155,0.0001463506,0.0002944711,0.000008403355,0.0002812917,8.633439e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001794806,"about_ca_system_score_gemma":0.0003151087,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002636773,"about_ca_topic_score_gemma":0.0001642331,"domain_scores_codex":[0.9983163,0.00005855971,0.0007783532,0.0002536701,0.0003264061,0.000266725],"domain_scores_gemma":[0.9987758,0.00009907795,0.0006553733,0.0001446323,0.0002354913,0.00008963478],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"observational","study_design_scores_codex":[0.2572401,0.0004980834,0.1840004,0.0004427865,0.0003213481,0.00001084008,0.006748171,0.001583389,0.4180726,0.000009589001,0.000008904576,0.1310638],"study_design_scores_gemma":[0.09250604,0.01361846,0.8586974,0.004013401,0.00003998483,0.00004600831,0.0007821272,0.00196054,0.02716586,0.000008115524,0.0008551357,0.0003068874],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9950321,0.002376372,0.0003111586,0.001035585,0.00009262599,0.001076193,0.00004244398,0.00001255437,0.00002092482],"genre_scores_gemma":[0.9944054,0.003779417,0.001413551,0.0002327132,0.00005847542,0.00001874599,0.00002034452,0.00005038798,0.00002100138],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.674697,"threshold_uncertainty_score":0.6246662,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2946884236","doi":"10.1186/s40425-019-0575-3","title":"CEA expression heterogeneity and plasticity confer resistance to the CEA-targeting bispecific immunotherapy antibody cibisatamab (CEA-TCB) in patient-derived colorectal cancer organoids","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Monoclonal and Polyclonal Antibodies Research","field":"Medicine","cited_by":115,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"Roche Innovation Center Zurich; National Institute for Health and Care Research; NIHR Biomedical Research Centre, Royal Marsden NHS Foundation Trust/Institute of Cancer Research; Sociedad Española de Oncología Médica; Cancer Research UK; Wellcome Trust","keywords":"Medicine; Colorectal cancer; Immunotherapy; Cancer immunotherapy; Organoid; Bispecific antibody; Cancer research; Antibody; Immunology; Cancer; Monoclonal antibody; Biology; Internal medicine; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.01788892149129567,"gpt":0.3402455607845739,"spread":0.3223566392932782,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0005040831,0.0003336643,0.0007175234,0.0002128647,0.0003308296,0.00008323494,0.0003107724,0.0001478354,0.000908101],"category_scores_gemma":[0.00005395068,0.0002149324,0.0002369482,0.0002960763,0.0001767311,0.0001643661,0.00007368249,0.0005798349,0.000007969147],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002577235,"about_ca_system_score_gemma":0.0003716341,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004393881,"about_ca_topic_score_gemma":0.0005206733,"domain_scores_codex":[0.9973552,0.0001557112,0.000790178,0.0004052137,0.0006786899,0.0006149656],"domain_scores_gemma":[0.998482,0.0002876956,0.0003843388,0.000240847,0.0004390656,0.0001660666],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.0163347,0.0001451107,0.07867897,0.0001420363,0.0002530748,0.000009336793,0.001546975,0.0001277993,0.8936099,0.00001443189,0.001358155,0.007779447],"study_design_scores_gemma":[0.006174091,0.001217446,0.1770268,0.001075186,0.00002758641,0.00003933626,0.0004817582,0.00022823,0.701502,0.0000624746,0.1118041,0.0003610179],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9703004,0.02443002,0.0002238789,0.002695833,0.0007578928,0.001311583,0.000190307,0.0000139377,0.0000761076],"genre_scores_gemma":[0.9822976,0.01520472,0.0005429946,0.0007506951,0.0003349771,0.0000971851,0.00001787489,0.00007126783,0.0006826812],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.192108,"threshold_uncertainty_score":0.9943069,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4205349336","doi":"10.1136/jitc-2021-003779","title":"Association of antibiotic treatment with immune-related adverse events in patients with cancer receiving immunotherapy","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":114,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"SKiN Health","funders":"Cancer Prevention and Research Institute of Texas","keywords":"Medicine; Lung cancer; Internal medicine; Adverse effect; Cancer; Retrospective cohort study; Adverse Event Reporting System; Antibiotics; Pharmacovigilance; Logistic regression; Oncology","retraction":null,"screen_n_in":null,"score":{"opus":0.008027828496329797,"gpt":0.2762625650620914,"spread":0.2682347365657616,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006578719,0.0003075656,0.000832186,0.0003776132,0.0002344852,0.000006044245,0.0001906978,0.0000976273,0.001076546],"category_scores_gemma":[0.000007997855,0.0002212014,0.0003855171,0.0006352392,0.00006966964,0.0001771837,0.00001330565,0.0003267401,2.463586e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.002931121,"about_ca_system_score_gemma":0.0007413955,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001504337,"about_ca_topic_score_gemma":0.0002367707,"domain_scores_codex":[0.9973872,0.0001384438,0.001020901,0.0002555207,0.000788698,0.0004092063],"domain_scores_gemma":[0.9974495,0.00009399276,0.001724883,0.0002907238,0.0003908907,0.00005001422],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.06311891,0.00134468,0.8346685,0.00007479639,0.004750732,0.000002876884,0.001785664,0.001066083,0.03147571,0.000002435576,0.00008099417,0.06162858],"study_design_scores_gemma":[0.06325807,0.01067425,0.906132,0.0009078985,0.0002916498,0.00001599287,0.0004252632,0.00004627452,0.009276228,0.00001898,0.008628285,0.000325101],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9855081,0.01147752,0.00002298544,0.0006657346,0.0006925497,0.001423943,0.0001360511,0.00001477655,0.00005831756],"genre_scores_gemma":[0.9876534,0.009152978,0.0002706913,0.000170016,0.00004809991,0.0001848778,0.00003153259,0.00009372537,0.00239472],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07146347,"threshold_uncertainty_score":0.9998366,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W1517732299","doi":"10.1186/s40425-015-0066-0","title":"Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":109,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Columbia College","funders":"National Cancer Institute","keywords":"Ipilimumab; Medicine; Liver transplantation; Melanoma; Transplantation; Metastatic melanoma; Oncology; Internal medicine; Cancer; Immunotherapy; Cancer research","retraction":null,"screen_n_in":null,"score":{"opus":0.02023009573251548,"gpt":0.3295934070659579,"spread":0.3093633113334424,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0006959185,0.0001050885,0.0003545268,0.0001356492,0.00003485084,0.000005714091,0.0001014582,0.00004991657,0.00003195121],"category_scores_gemma":[0.00002521592,0.00006860367,0.0001341965,0.0001970259,0.00006107279,0.00008075929,0.000003264122,0.00009690248,8.123497e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00008937978,"about_ca_system_score_gemma":0.0001584405,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003325869,"about_ca_topic_score_gemma":0.0001348285,"domain_scores_codex":[0.9989262,0.00005591473,0.0005477499,0.00009259601,0.000246198,0.0001313071],"domain_scores_gemma":[0.9991751,0.0001746713,0.0003092165,0.0001271114,0.0001750626,0.00003888163],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"observational","study_design_scores_codex":[0.1205213,0.0002035777,0.00694514,0.0003411545,0.0002453485,0.000005206236,0.02171,0.0002439006,0.2835704,0.00002940584,0.000159284,0.5660253],"study_design_scores_gemma":[0.07583696,0.006953154,0.6948488,0.002064226,0.000329269,0.000300286,0.003253186,0.0001393175,0.1995397,0.0001347306,0.01631354,0.0002868712],"study_design_candidate":"observational","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9814464,0.01616921,0.0004423113,0.001009413,0.0001371755,0.0005875321,0.00003632912,0.00000278346,0.0001688535],"genre_scores_gemma":[0.9836422,0.01490311,0.001008525,0.0002607754,0.00005924974,0.00001656677,0.000003709381,0.00001608074,0.00008977394],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.6879036,"threshold_uncertainty_score":0.2797577,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2795166918","doi":"10.1186/s40425-017-0313-7","title":"Mathematical modeling of tumor-associated macrophage interactions with the cancer microenvironment","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":108,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto Metropolitan University","funders":"National Institute of General Medical Sciences; National Cancer Institute; National Institutes of Health; National Science Foundation","keywords":"Tumor microenvironment; Tumor progression; Cancer research; Angiogenesis; Macrophage; Population; Cancer; Medicine; Monocyte; Immunology; Chemistry; Internal medicine; Tumor cells; In vitro","retraction":null,"screen_n_in":null,"score":{"opus":0.0158989538304639,"gpt":0.3001841164475346,"spread":0.2842851626170707,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0004149902,0.0001865535,0.0003944767,0.00007441231,0.0003275865,0.00001509636,0.000415951,0.00008435873,0.006070441],"category_scores_gemma":[0.00001740715,0.0001142823,0.0002068515,0.0001098151,0.0005519333,0.00009154786,0.00003465367,0.0003792845,0.00001866764],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002447053,"about_ca_system_score_gemma":0.000167073,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001558342,"about_ca_topic_score_gemma":0.0000911446,"domain_scores_codex":[0.9987832,0.00009041887,0.0005493771,0.0001602099,0.00009127874,0.0003254983],"domain_scores_gemma":[0.9986165,0.0001297676,0.0006581581,0.0002871669,0.0002942245,0.00001415727],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002711714,0.000251274,0.0002282331,0.00004408899,0.002088787,7.560225e-7,0.00203849,0.001498191,0.9739494,0.00007665171,0.004038624,0.01307377],"study_design_scores_gemma":[0.006280412,0.00146055,0.0005963882,0.0008896319,0.0003665969,0.0001333821,0.0009432575,0.00107091,0.8457076,0.0006144433,0.1415696,0.0003672314],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9481502,0.03985458,0.007623713,0.001303066,0.001851785,0.0005661065,0.0001198727,0.0000163162,0.0005143516],"genre_scores_gemma":[0.9908093,0.002007569,0.0004737322,0.0003361808,0.0001315215,0.0001282347,0.000003760695,0.00005485467,0.006054842],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.137531,"threshold_uncertainty_score":0.9948381,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3173127935","doi":"10.1136/jitc-2020-002157","title":"Follicular helper-T cells restore CD8<sup>+</sup>-dependent antitumor immunity and anti-PD-L1/PD-1 efficacy","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":106,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Centre Hospitalier de l’Université de Montréal; Université Laval; Institut universitaire de cardiologie et de pneumologie de Québec","funders":"Ligue Contre le Cancer; Agence Nationale de la Recherche; Université de Franche-Comté; Fondation de France; Université Laval; Université de Bourgogne; Association pour la Recherche sur le Cancer","keywords":"Germinal center; Cytotoxic T cell; Immune system; CD8; Chemokine; Immunology; Cancer research; Biology; T cell; Adoptive cell transfer; Antibody; Flow cytometry; Cytokine; B cell; In vitro","retraction":null,"screen_n_in":null,"score":{"opus":0.02059658743093797,"gpt":0.3176562006179244,"spread":0.2970596131869864,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0008214799,0.0004097187,0.0009738231,0.0002222401,0.0004515073,0.0001254824,0.0002772724,0.0002260197,0.0009431696],"category_scores_gemma":[0.00005864193,0.0003431762,0.0007384352,0.0003658817,0.000260588,0.0002310024,0.00005121713,0.0005953106,0.000003420587],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003205114,"about_ca_system_score_gemma":0.0008257376,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003372239,"about_ca_topic_score_gemma":0.00002655249,"domain_scores_codex":[0.9972563,0.0001531206,0.0009624896,0.0004077296,0.0006574246,0.0005628753],"domain_scores_gemma":[0.9978631,0.0001649522,0.0005238455,0.0006316823,0.0006171595,0.0001992916],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.009754391,0.0006310969,0.003916485,0.0003177851,0.002200812,0.0001408901,0.001467846,0.0001623528,0.9227654,0.00003259087,0.004317946,0.05429238],"study_design_scores_gemma":[0.03000942,0.001570254,0.04498212,0.001746648,0.0005401311,0.001449883,0.001518649,0.000214767,0.5771221,0.0001261196,0.3399548,0.0007651072],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9002659,0.0953669,0.0002971013,0.002042676,0.001048594,0.0006678201,0.00009880339,0.00003443018,0.0001777975],"genre_scores_gemma":[0.9016868,0.0891996,0.001917013,0.001870223,0.0007679886,0.00005948829,0.00002985128,0.0001440766,0.004324885],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3456433,"threshold_uncertainty_score":0.9999701,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4297387081","doi":"10.1136/jitc-2022-005187","title":"GD2-targeting CAR-T cells enhanced by transgenic IL-15 expression are an effective and clinically feasible therapy for glioblastoma","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":105,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Occupational Cancer Research Centre","funders":"Mark Hughes Foundation; Medical Research Council; Flinders Foundation; Tour de Cure; Australian Cancer Research Foundation; Fay Fuller Foundation; Cancer Australia; Cancer Council South Australia; Neurosurgical Research Foundation; National Health and Medical Research Council; Hospital Research Foundation","keywords":"Chimeric antigen receptor; Medicine; Glioma; Flow cytometry; Cancer research; Brain tumor; Antigen; Immune system; Immunotherapy; Tumor antigen; Pathology; Oncology; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.02121667910910916,"gpt":0.3714376681463423,"spread":0.3502209890372331,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.001742061,0.0002986093,0.000786381,0.0001996027,0.0006239467,0.00005645274,0.0003013448,0.0001339582,0.002008677],"category_scores_gemma":[0.00004190185,0.0002505281,0.0005425254,0.0002231826,0.0001281154,0.0001823662,0.00002739168,0.0006759699,3.471185e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000314731,"about_ca_system_score_gemma":0.0002735841,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00003990449,"about_ca_topic_score_gemma":0.0000130217,"domain_scores_codex":[0.9972492,0.0002970839,0.0007933325,0.0004344354,0.0006821115,0.0005438334],"domain_scores_gemma":[0.9978374,0.000566735,0.0006180159,0.000307577,0.000454709,0.0002155725],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.04001449,0.0004039124,0.000432482,0.00009575854,0.000413256,0.000001283918,0.001658207,0.00009074553,0.7972732,0.000001059218,0.003178967,0.1564367],"study_design_scores_gemma":[0.01869885,0.01390825,0.0006554515,0.0001593823,0.00005377185,0.00001836906,0.001010906,0.0001529794,0.8631942,0.0001775093,0.101708,0.000262306],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9762477,0.01656755,0.002403759,0.0005433706,0.0007405306,0.003108631,0.0003258284,0.00003143554,0.00003115003],"genre_scores_gemma":[0.974937,0.01670866,0.001719085,0.0008869673,0.0006907419,0.001742134,0.00002659523,0.0002024702,0.003086312],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1561744,"threshold_uncertainty_score":0.9999947,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4280541127","doi":"10.1136/jitc-2021-004076","title":"Anti-CSF-1R emactuzumab in combination with anti-PD-L1 atezolizumab in advanced solid tumor patients naïve or experienced for immune checkpoint blockade","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":104,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"","funders":"Cilag; Foundation Medicine; Takeda Oncology; Chugai Pharmaceutical; Novartis Pharma; Genentech; Daiichi Sankyo Europe; National Cancer Institute; Servier; Eisai; Basilea Pharmaceutica; AstraZeneca; Institut National Du Cancer; Seagen; Agios Pharmaceuticals; Eisai Canada; BeiGene; Clovis Oncology; Loxo Oncology; Astex Pharmaceuticals; Les Laboratories Pierre Fabre; Boston Pharmaceuticals; Taiho Pharmaceutical; F. Hoffmann-La Roche; Yale University; Bayer HealthCare; Exelixis; Sanofi; GlaxoSmithKline; Amgen; Pfizer; Celgene; Eli Lilly and Company; Bristol-Myers Squibb","keywords":"Atezolizumab; Blockade; Solid tumor; Medicine; Immune checkpoint; Immune system; Oncology; Cancer research; Internal medicine; Immunology; Immunotherapy; Pembrolizumab; Cancer; Receptor","retraction":null,"screen_n_in":null,"score":{"opus":0.01447742620359424,"gpt":0.325284274372232,"spread":0.3108068481686377,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow"],"consensus_categories":[],"category_scores_codex":[0.0006289083,0.0003595008,0.001002939,0.0005488593,0.0003274417,0.00004152631,0.0003299288,0.00008301668,0.0004583306],"category_scores_gemma":[0.00005475037,0.0002807076,0.0003748511,0.000692623,0.0001418661,0.0003227,0.00003547313,0.000454386,2.553597e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001877718,"about_ca_system_score_gemma":0.001124437,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003946761,"about_ca_topic_score_gemma":0.0001217905,"domain_scores_codex":[0.9969502,0.00007462144,0.00133763,0.000382468,0.0006521847,0.0006028981],"domain_scores_gemma":[0.9981076,0.0001013854,0.001019155,0.0003145082,0.0003818225,0.00007549689],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.2331941,0.003375557,0.01682321,0.0004499041,0.0008348254,0.00005359176,0.01022837,0.00308418,0.6592176,0.00002942755,0.0001157762,0.07259351],"study_design_scores_gemma":[0.2266771,0.02297205,0.251354,0.002261552,0.0001337092,0.0003406808,0.006815892,0.0008919504,0.4687037,0.0004722082,0.01829544,0.00108172],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9901083,0.00480001,0.0002742586,0.0009244584,0.000990004,0.002750743,0.0001038205,0.00002166929,0.00002681394],"genre_scores_gemma":[0.9946082,0.002087137,0.001027055,0.0004440364,0.00007301005,0.001382609,0.00004527125,0.0001015067,0.0002312357],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2345308,"threshold_uncertainty_score":0.9999645,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3201513519","doi":"10.1136/jitc-2021-002954","title":"Mitochondrial reactive oxygen species trigger metformin-dependent antitumor immunity via activation of Nrf2/mTORC1/p62 axis in tumor-infiltrating CD8T lymphocytes","year":2021,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Metabolism, Diabetes, and Cancer","field":"Biochemistry, Genetics and Molecular Biology","cited_by":101,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Artificial Intelligence in Medicine (Canada)","funders":"Japan Society for the Promotion of Science; Ono Pharmaceutical; Secom Science and Technology Foundation","keywords":"mTORC1; Mitochondrial ROS; Cancer research; Glutaminolysis; Reactive oxygen species; Mitochondrion; Metformin; Chemistry; Biology; Cell biology; Cancer cell; Cancer; Signal transduction; PI3K/AKT/mTOR pathway; Endocrinology","retraction":null,"screen_n_in":null,"score":{"opus":0.01487345650998473,"gpt":0.2909870561444415,"spread":0.2761135996344568,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003981343,0.0002162095,0.0005101222,0.0001177095,0.0001225727,0.00003566813,0.0002425256,0.0001261267,0.0002237267],"category_scores_gemma":[0.000143851,0.000197198,0.0003266191,0.0001806058,0.00008756081,0.00004386568,0.00003369272,0.000186306,3.22113e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001667693,"about_ca_system_score_gemma":0.0007525802,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002896893,"about_ca_topic_score_gemma":0.0001526615,"domain_scores_codex":[0.9983196,0.0001198379,0.000720555,0.0002369655,0.0003104017,0.0002926594],"domain_scores_gemma":[0.9982808,0.00005950506,0.0007393694,0.0002979616,0.0005726886,0.00004970844],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.00153267,0.0001335688,0.0006724082,0.00005300125,0.0003566175,0.000001859728,0.0003385759,0.0001329542,0.9493672,0.00003074452,0.0002689266,0.04711143],"study_design_scores_gemma":[0.003573777,0.0002484305,0.002735375,0.000129393,0.00003720175,0.00002046582,0.0004877885,0.00001714513,0.9242465,0.0002532398,0.06804982,0.0002008419],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8753328,0.1221869,0.001018364,0.00002980988,0.0009263418,0.000256842,0.00007320231,0.000003226694,0.0001724846],"genre_scores_gemma":[0.9141299,0.08174496,0.001462928,0.00026029,0.001309371,0.0001012822,0.0000707581,0.00006450971,0.0008559963],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.0677809,"threshold_uncertainty_score":0.8041502,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2298802783","doi":"10.1186/s40425-016-0116-2","title":"Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Virus-based gene therapy research","field":"Biochemistry, Genetics and Molecular Biology","cited_by":99,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Institute of Cancer Research","funders":"University of California, San Diego; U.S. Food and Drug Administration; Amgen","keywords":"Medicine; Oncolytic virus; Melanoma; Internal medicine; Oncology; Cancer research; Cancer","retraction":null,"screen_n_in":null,"score":{"opus":0.02881937285232573,"gpt":0.3572661509682807,"spread":0.328446778115955,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003050731,0.0001991157,0.000279914,0.0001207002,0.0001525742,0.00001509114,0.0002542693,0.00009491019,0.00008815523],"category_scores_gemma":[0.00003254934,0.000120298,0.0001159354,0.0001062389,0.0001396535,0.00001350421,0.00002753621,0.00008619888,0.000001066745],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002046915,"about_ca_system_score_gemma":0.000440311,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0002474182,"about_ca_topic_score_gemma":0.001515061,"domain_scores_codex":[0.9985898,0.0001723614,0.0003981426,0.0002699599,0.0003011243,0.0002686714],"domain_scores_gemma":[0.999084,0.00005035643,0.0002220929,0.0002658901,0.0003090581,0.00006860594],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.2181185,0.001380126,0.03285583,0.000005454401,0.0007220753,0.00001038168,0.0001508599,0.0001277488,0.6808147,4.533867e-7,0.00004556068,0.0657683],"study_design_scores_gemma":[0.1501964,0.08441024,0.01429173,0.0002661052,0.00006870022,0.00001720523,0.0002959118,0.00007647051,0.7465612,0.000005736855,0.00338871,0.000421548],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9926774,0.004855964,0.0011745,0.00005186888,0.0002038544,0.0006517135,0.0003751427,0.00000507726,0.000004472552],"genre_scores_gemma":[0.9985403,0.0006637297,0.0001294401,0.0000359147,0.00012262,0.000159054,0.00002736256,0.00003689903,0.0002846622],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.08303012,"threshold_uncertainty_score":0.4905611,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3036508677","doi":"10.1136/jitc-2020-000840","title":"Chronic immune checkpoint inhibitor pneumonitis","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":96,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"Bloomberg~Kimmel Institute for Cancer Immunotherapy, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins University; National Cancer Institute; National Heart, Lung, and Blood Institute","keywords":"Medicine; Pneumonitis; Immunosuppression; Hypersensitivity pneumonitis; Internal medicine; Bronchoalveolar lavage; Immunology; Gastroenterology; Lung","retraction":null,"screen_n_in":null,"score":{"opus":0.02450206369274763,"gpt":0.3195411143344083,"spread":0.2950390506416607,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003006966,0.0002393754,0.0006207691,0.0001039047,0.0001602483,0.00004058761,0.0002049405,0.0001225016,0.001440647],"category_scores_gemma":[0.00003120873,0.0001944891,0.000819337,0.0002646306,0.0001403452,0.0001534913,0.0000168994,0.0003491159,0.000005834892],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0003774385,"about_ca_system_score_gemma":0.0006791555,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00008457739,"about_ca_topic_score_gemma":0.000008741867,"domain_scores_codex":[0.9981288,0.00002966657,0.0008973596,0.0002131157,0.0003724667,0.000358592],"domain_scores_gemma":[0.9987502,0.00004529358,0.0005380954,0.0002134659,0.0002947982,0.0001581402],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.007181028,0.00005811467,0.0005598075,0.000206051,0.0008178901,0.000008050524,0.0005868475,0.0000125645,0.7806045,0.0000136799,0.001771704,0.2081798],"study_design_scores_gemma":[0.01378503,0.003704619,0.008996957,0.0006163263,0.000134134,0.0001607747,0.0001659503,0.0001146126,0.5032645,0.00007981706,0.4687035,0.0002737308],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.6766221,0.2711462,0.001685137,0.04531958,0.00284392,0.001506552,0.0001132839,0.00009242397,0.0006707999],"genre_scores_gemma":[0.9510534,0.0389977,0.001128764,0.003212283,0.003870643,0.0001195722,0.00001244382,0.0001298818,0.001475337],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4669318,"threshold_uncertainty_score":0.9994721,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2921822469","doi":"10.1186/s40425-019-0521-4","title":"The IL-1/IL-1 receptor axis and tumor cell released inflammasome adaptor ASC are key regulators of TSLP secretion by cancer associated fibroblasts in pancreatic cancer","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Inflammasome and immune disorders","field":"Biochemistry, Genetics and Molecular Biology","cited_by":94,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pancreas Centre (Canada)","funders":"Associazione Italiana per la Ricerca sul Cancro; Worldwide Cancer Research","keywords":"Inflammasome; Signal transducing adaptor protein; Pancreatic cancer; Secretion; Cancer research; Cancer; Receptor; Medicine; Chemistry; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.003735799338267266,"gpt":0.2335305472925836,"spread":0.2297947479543164,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0003942199,0.0002429583,0.0004268593,0.00007493165,0.0001358455,0.00003115219,0.0002445777,0.0001814623,0.0001063403],"category_scores_gemma":[0.00005386614,0.0001902347,0.0002123476,0.0001512265,0.0001212334,0.00002666751,0.00002834982,0.0002050235,5.25123e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001396176,"about_ca_system_score_gemma":0.0003149688,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008608582,"about_ca_topic_score_gemma":0.0006868898,"domain_scores_codex":[0.9983917,0.0001100827,0.0006441392,0.0002447351,0.0002458223,0.0003635625],"domain_scores_gemma":[0.9983049,0.00005715202,0.001007511,0.0002582893,0.0003209382,0.00005122191],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002139653,0.00005355201,0.03879086,0.0001047409,0.0003464977,1.669025e-7,0.0002754465,0.0002686208,0.9508039,0.000004079283,0.003468688,0.00374379],"study_design_scores_gemma":[0.006017804,0.0008536623,0.04646425,0.0007129463,0.00006135941,0.000001814613,0.0006148406,0.0001915948,0.8162353,0.00005788366,0.1283895,0.0003990115],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9554126,0.04281236,0.00001125057,0.0003454465,0.0004862435,0.0005168783,0.0003804065,0.00000419762,0.00003058365],"genre_scores_gemma":[0.9483718,0.04880053,0.00003889531,0.0001424787,0.0001148233,0.0001457389,0.00004271343,0.00005895748,0.002284074],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1345686,"threshold_uncertainty_score":0.7757548,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2157899115","doi":"10.1186/s40425-014-0041-1","title":"Retinal vasculitis and ocular vitreous metastasis following complete response to PD-1 inhibition in a patient with metastatic cutaneous melanoma","year":2014,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Ocular Oncology and Treatments","field":"Medicine","cited_by":90,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Toronto Western Hospital; University of Toronto; University Health Network","funders":"","keywords":"Medicine; Retinal vasculitis; Extravasation; Pembrolizumab; Melanoma; Vasculitis; Metastasis; Retinal; Nivolumab; Optic nerve; Vitreous hemorrhage; Immune system; Immunotherapy; Pathology; Ophthalmology; Cancer research; Immunology; Retinal detachment; Internal medicine; Cancer; Disease","retraction":null,"screen_n_in":null,"score":{"opus":0.01311145904582377,"gpt":0.301956724692727,"spread":0.2888452656469032,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004968835,0.0001569012,0.0005107643,0.0002108737,0.0001096663,0.00001677872,0.0000312879,0.00004212539,0.00004606126],"category_scores_gemma":[0.0000640559,0.000114517,0.0001800272,0.0001366566,0.00004567508,0.00006601652,0.000008575787,0.0001394612,0.000001121124],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001865117,"about_ca_system_score_gemma":0.000109916,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009475694,"about_ca_topic_score_gemma":0.00008817619,"domain_scores_codex":[0.9987748,0.0002117994,0.0003663395,0.0001711898,0.000254825,0.0002210946],"domain_scores_gemma":[0.9992935,0.0001793852,0.0001875452,0.0001391614,0.0001035075,0.00009691371],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.191124,0.001399911,0.03004405,0.0003182536,0.009466697,0.007922163,0.008676975,0.000614264,0.2470436,0.00009562972,0.0002437616,0.5030507],"study_design_scores_gemma":[0.1846426,0.1492398,0.1777993,0.00843455,0.007727438,0.06600525,0.002920634,0.001228183,0.1554643,0.003767396,0.2406062,0.002164285],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9931362,0.003107204,0.001687837,0.001279973,0.0001178965,0.0006107367,0.00002533707,0.000006943209,0.00002782948],"genre_scores_gemma":[0.9885969,0.0002277749,0.01034026,0.000630073,0.0000265486,0.00007971582,0.000005325179,0.00002843678,0.000064978],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5008864,"threshold_uncertainty_score":0.4669869,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2906255446","doi":"10.1186/s40425-018-0457-0","title":"PI3Kα/δ inhibition promotes anti-tumor immunity through direct enhancement of effector CD8+ T-cell activity","year":2018,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":89,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"AstraZeneca (Canada)","funders":"AstraZeneca","keywords":"PI3K/AKT/mTOR pathway; Tumor microenvironment; Immune system; CD8; Cancer research; T cell; Effector; Cytotoxic T cell; Immunosuppression; Immunotherapy; Biology; Chemistry; Pharmacology; Immunology; Medicine; Cell biology; In vitro; Signal transduction; Biochemistry","retraction":null,"screen_n_in":null,"score":{"opus":0.01591630376453932,"gpt":0.30009173386688,"spread":0.2841754301023406,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0005062585,0.0002154182,0.0004936853,0.0001251968,0.0003464504,0.00001817471,0.0001602804,0.0001431414,0.002609612],"category_scores_gemma":[0.00004480203,0.0001773648,0.0003276003,0.0001418406,0.0002743756,0.0003532637,0.00002499064,0.000342919,0.00003664189],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001392397,"about_ca_system_score_gemma":0.0001302802,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003765649,"about_ca_topic_score_gemma":0.00001635078,"domain_scores_codex":[0.9986423,0.0002369545,0.0005679982,0.0001797599,0.00008308,0.0002899503],"domain_scores_gemma":[0.9981003,0.0001503942,0.0009490054,0.0002542439,0.0005325024,0.00001358225],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.003269414,0.0005735888,0.0002590337,0.00008865811,0.0004325936,2.418547e-7,0.0007528128,0.00000152884,0.9782678,0.00001111013,0.00501464,0.01132861],"study_design_scores_gemma":[0.003171288,0.002453727,0.001929062,0.0002272981,0.00005817923,0.00002170905,0.00009593468,0.000004935124,0.9107976,0.0000546146,0.08102319,0.0001624633],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.981578,0.006799478,0.002780895,0.0001266001,0.006960285,0.0005209739,0.00002712221,0.00002184878,0.001184831],"genre_scores_gemma":[0.9941298,0.001683993,0.000147919,0.0001409998,0.0001582587,0.0000543525,0.00001817706,0.00003046911,0.003635988],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07600856,"threshold_uncertainty_score":0.9983022,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2914393875","doi":"10.1186/s40425-018-0485-9","title":"Tumor microenvironment modulation enhances immunologic benefit of chemoradiotherapy","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":89,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Pediatric Oncology Group","funders":"National Center for Advancing Translational Sciences; National Center for Research Resources; National Institute of Dental and Craniofacial Research; National Institute of Diabetes and Digestive and Kidney Diseases; Swim Across America; National Institute of General Medical Sciences; KWF Kankerbestrijding; National Cancer Institute; National Institutes of Health; Cancer Prevention and Research Institute of Texas; National Institute of Allergy and Infectious Diseases; Deutsche Krebshilfe; Irving Medical Center, Columbia University; Owens Foundation; University of Texas MD Anderson Cancer Center","keywords":"Tumor microenvironment; Immune system; Head and neck squamous-cell carcinoma; Cancer research; Medicine; CD8; T cell; Mass cytometry; Myeloid; Antigen; Immunology; Cancer; Head and neck cancer; Biology; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.008691542132802798,"gpt":0.2691522417700022,"spread":0.2604606996371994,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003903055,0.0002515853,0.0007095816,0.0001586808,0.0001165448,0.00001206931,0.0004648524,0.0001824252,0.0044735],"category_scores_gemma":[0.000008870602,0.0002113538,0.0003838645,0.0001165656,0.0002437496,0.000164055,0.00002560298,0.000289004,0.00002769177],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002261609,"about_ca_system_score_gemma":0.0001098741,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001082139,"about_ca_topic_score_gemma":0.000005513175,"domain_scores_codex":[0.998403,0.00006044688,0.0008275653,0.0002383186,0.00009949069,0.0003711629],"domain_scores_gemma":[0.9981745,0.000121608,0.001125531,0.0003889949,0.0001769239,0.00001238834],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001867981,0.000144632,0.003310582,0.0000705075,0.0007763828,2.201255e-7,0.0004351483,0.0007098528,0.9387568,0.00008871296,0.000373419,0.05346582],"study_design_scores_gemma":[0.004736022,0.0008190947,0.01556314,0.0001796622,0.00003587495,0.00003523445,0.000122572,0.00001710845,0.9062225,0.0005091708,0.07153486,0.0002247251],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.8870172,0.1083705,0.0003361804,0.0001650831,0.003361955,0.0005534121,0.00004558008,0.00001304251,0.0001370515],"genre_scores_gemma":[0.9781321,0.01478153,0.0008536634,0.0002091932,0.00007457715,0.00006321082,0.00001160614,0.00005304462,0.00582102],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.09358896,"threshold_uncertainty_score":0.9964365,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2947794723","doi":"10.1186/s40425-019-0602-4","title":"Toward a comprehensive view of cancer immune responsiveness: a synopsis from the SITC workshop","year":2019,"lang":"en","type":"review","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":88,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ontario Institute for Cancer Research; Caprion (Canada); Princess Margaret Cancer Centre; Jewish General Hospital; University of Toronto; University Health Network","funders":"National Center for Advancing Translational Sciences; Society for Immunotherapy of Cancer; National Cancer Institute; Celgene","keywords":"Premise; Cancer; Cancer immunotherapy; Immune escape; Immune system; Immunotherapy; Computational biology; Bioinformatics; Medicine; Immunology; Psychology; Biology; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.1124544231922615,"gpt":0.4196030258259771,"spread":0.3071486026337156,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0007721254,0.0008581903,0.005129877,0.000331256,0.0002032131,0.00006713803,0.001003277,0.000597855,0.001641856],"category_scores_gemma":[0.00007510874,0.0005136753,0.004107918,0.000785823,0.0004047187,0.0001339865,0.00007639491,0.001071463,0.000005537241],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0007559713,"about_ca_system_score_gemma":0.003377965,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002090258,"about_ca_topic_score_gemma":0.0001005984,"domain_scores_codex":[0.9950481,0.0004178103,0.00262781,0.0005162645,0.0008175917,0.0005724203],"domain_scores_gemma":[0.9919796,0.002040684,0.003636748,0.001119189,0.001120619,0.0001031708],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.01199507,0.0001453044,0.00003214465,0.01142182,0.01396082,0.000008342686,0.0008113717,0.000007131185,0.002545793,0.000008232348,0.004722884,0.9543411],"study_design_scores_gemma":[0.004921595,0.0005297926,0.0003400935,0.08482946,0.004191369,0.00009441595,0.0003134148,0.000003439991,0.0003932864,0.00003709982,0.9038746,0.0004714458],"study_design_candidate":"design_other","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.0008758338,0.9892766,0.00008067281,0.001628511,0.003429224,0.003279523,0.001374936,0.000019092,0.00003557502],"genre_scores_gemma":[0.00008630256,0.9949322,0.0002632207,0.0009332951,0.0009005837,0.0005907569,0.00007910612,0.0002217535,0.001992806],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.9538696,"threshold_uncertainty_score":0.9997315,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3011361209","doi":"10.1136/jitc-2020-000530","title":"A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":87,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre","funders":"National Center for Advancing Translational Sciences; National Cancer Institute; Novartis Pharmaceuticals Corporation","keywords":"Medicine; Nausea; Adverse effect; Internal medicine; Response Evaluation Criteria in Solid Tumors; Pharmacokinetics; Gastroenterology; Tolerability; Antibody; Lung cancer; Oncology; Population; Monoclonal antibody; Toxicity; Phases of clinical research; Immunology","retraction":null,"screen_n_in":null,"score":{"opus":0.02102198637447333,"gpt":0.3722325480268819,"spread":0.3512105616524085,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002773078,0.0002469455,0.0008157981,0.0002776806,0.0000936764,0.00001993348,0.0001811543,0.00007273884,0.0001671215],"category_scores_gemma":[0.00001503086,0.000194875,0.00015455,0.0004893538,0.00008675415,0.0003500672,0.00001043324,0.000246027,1.650615e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001921786,"about_ca_system_score_gemma":0.0001889467,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004110656,"about_ca_topic_score_gemma":0.000522321,"domain_scores_codex":[0.9978291,0.0000611723,0.001059206,0.0002725607,0.0004787766,0.0002991958],"domain_scores_gemma":[0.998619,0.00002992866,0.0007518607,0.0002410334,0.0002573052,0.0001009238],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.150451,0.008734377,0.6354318,0.0002915938,0.0007297357,0.00002542022,0.009948977,0.002114801,0.1429953,0.000004668339,0.0000483977,0.04922396],"study_design_scores_gemma":[0.1167454,0.03297134,0.8389878,0.0008985554,0.0000784596,0.000005784772,0.001040848,0.0004783582,0.007815571,0.00001664664,0.0006967652,0.000264502],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9965124,0.001180499,0.00007924635,0.0002930291,0.0001600589,0.00171616,0.00003017921,0.00001223385,0.00001624348],"genre_scores_gemma":[0.9989074,0.0004869748,0.0001689773,0.0002003678,0.00008709096,0.00005249611,0.00002595532,0.00005496989,0.00001570569],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.203556,"threshold_uncertainty_score":0.794677,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2948878352","doi":"10.1186/s40425-019-0619-8","title":"DNA damage repair gene mutations and their association with tumor immune regulatory gene expression in muscle invasive bladder cancer subtypes","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Bladder and Urothelial Cancer Treatments","field":"Medicine","cited_by":84,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Queen's University","funders":"Southeastern Ontario Academic Medical Organization; Queen's University","keywords":"Immunoediting; Bladder cancer; Immune checkpoint; DNA repair; Immune system; Gene; Cancer; Cancer research; DNA mismatch repair; Immunotherapy; Tumor microenvironment; Medicine; Bioinformatics; Biology; Immunology; Genetics; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.01039549257959938,"gpt":0.275885229973412,"spread":0.2654897373938127,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002741568,0.0001995821,0.0004585281,0.0001549484,0.0001101618,0.00002224977,0.00007581437,0.00009003763,0.0003596827],"category_scores_gemma":[0.00001856816,0.0001374742,0.0001594015,0.0001547079,0.00004798111,0.0002179724,0.00001201134,0.0002034308,0.0000010786],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005049428,"about_ca_system_score_gemma":0.000576036,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0004082809,"about_ca_topic_score_gemma":0.0002706161,"domain_scores_codex":[0.9987871,0.00005326005,0.0004148567,0.0002207329,0.0002720531,0.0002519858],"domain_scores_gemma":[0.9988381,0.0001033399,0.0004731418,0.0002214993,0.0002972671,0.00006668422],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.001898836,0.0001440944,0.154721,0.00007546866,0.0007073854,0.0000057999,0.00201382,0.0001518263,0.8363015,0.000003218892,0.0002527384,0.003724312],"study_design_scores_gemma":[0.007835858,0.0006421006,0.4552015,0.0004862014,0.0001061834,0.00002178329,0.0004173414,0.00004096171,0.5331228,0.0001007927,0.001876361,0.000148115],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9798083,0.0183196,0.00004231024,0.0004779157,0.0003565945,0.00079952,0.00009287269,0.00002010243,0.00008283475],"genre_scores_gemma":[0.9915912,0.004949074,0.001011919,0.0004162235,0.000200377,0.0001871021,0.00001570025,0.00006128922,0.001567099],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3031788,"threshold_uncertainty_score":0.5606036,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3112961014","doi":"10.1136/jitc-2020-001849","title":"Galectin-9 expression defines exhausted T cells and impaired cytotoxic NK cells in patients with virus-associated solid tumors","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Galectins and Cancer Biology","field":"Immunology and Microbiology","cited_by":82,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"Faculty of Medicine and Dentistry, University of Alberta; Canadian Institutes of Health Research; University of Alberta; Alberta Cancer Foundation","keywords":"TIGIT; Cytotoxic T cell; T cell; Downregulation and upregulation; IL-2 receptor; Cancer research; Interleukin 21; Immunology; Galectin; CD8; Biology; Medicine; Immune system; In vitro","retraction":null,"screen_n_in":null,"score":{"opus":0.0109078295511333,"gpt":0.2508194246248309,"spread":0.2399115950736976,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001701997,0.0002311985,0.0005529953,0.0001106707,0.0001779646,0.00001816933,0.0001797534,0.0002127731,0.0003554205],"category_scores_gemma":[0.00001891981,0.0001705789,0.0001111736,0.0001883536,0.0001300785,0.00009636216,0.00002558524,0.0003542516,0.000002503263],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00009114926,"about_ca_system_score_gemma":0.0001366704,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.000149954,"about_ca_topic_score_gemma":0.0001369385,"domain_scores_codex":[0.9986565,0.0001329717,0.0005154786,0.000245863,0.00006038753,0.000388844],"domain_scores_gemma":[0.9990349,0.00007835771,0.0005512199,0.0001079391,0.000186725,0.00004090481],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.005441725,0.0001761,0.03922832,0.00003175296,0.000240493,0.000001163688,0.0007638326,0.00005213175,0.9493032,0.00000116761,0.001907095,0.002853078],"study_design_scores_gemma":[0.0120958,0.002921684,0.1035956,0.0002378775,0.00003652796,0.000006228745,0.0001465664,0.000007000692,0.8753477,0.00002905528,0.005309327,0.000266603],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9938427,0.004809998,0.00004527088,0.0001397319,0.0005621383,0.0004374347,0.0001235592,0.00001892425,0.0000202266],"genre_scores_gemma":[0.9976428,0.001464153,0.00008152178,0.000444691,0.00004476937,0.00004287105,0.00001816211,0.0000376822,0.0002234124],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.07395545,"threshold_uncertainty_score":0.6956006,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2916703154","doi":"10.1186/s40425-019-0507-2","title":"Human double negative T cells target lung cancer via ligand-dependent mechanisms that can be enhanced by IL-15","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune Cell Function and Interaction","field":"Immunology and Microbiology","cited_by":81,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; Mount Sinai Hospital; Toronto General Hospital; University of Toronto; University Health Network","funders":"Canadian Cancer Society Research Institute; Canadian Institutes of Health Research","keywords":"Lung cancer; Cancer; Cancer research; Ligand (biochemistry); Medicine; Computational biology; Bioinformatics; Chemistry; Biology; Immunology; Oncology; Receptor; Internal medicine","retraction":null,"screen_n_in":null,"score":{"opus":0.01122254260838088,"gpt":0.2874408932894919,"spread":0.276218350681111,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["metaepi_narrow","insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0003079385,0.0003182335,0.0005528738,0.000158003,0.0004010154,0.0000515158,0.0003249331,0.0002878652,0.01322061],"category_scores_gemma":[0.000003245774,0.0002713315,0.0003470976,0.00009747179,0.00007859959,0.000298466,0.00002773686,0.0005812519,0.000030165],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000389038,"about_ca_system_score_gemma":0.0001617232,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001539353,"about_ca_topic_score_gemma":0.0001548662,"domain_scores_codex":[0.9983981,0.00009426588,0.0005916142,0.0003067745,0.000132821,0.000476462],"domain_scores_gemma":[0.9984869,0.00006190608,0.0008310317,0.0002604503,0.0003242604,0.00003546633],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.002239496,0.0001237451,0.00008715215,0.00003507334,0.001095169,2.413694e-7,0.001175025,0.0001571615,0.9563712,0.00007365342,0.036835,0.001807067],"study_design_scores_gemma":[0.007052604,0.0005601846,0.00006871388,0.0001172458,0.0000688314,0.00001049979,0.0004568806,0.00001537629,0.8899001,0.0002384851,0.1012211,0.0002899166],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9213653,0.02521202,0.01254005,0.001455539,0.0359606,0.001868049,0.0002927617,0.00007956103,0.001226151],"genre_scores_gemma":[0.8882201,0.003038983,0.0001037027,0.001201577,0.0001122052,0.0001778112,0.00005768438,0.00007397986,0.107014],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.1057878,"threshold_uncertainty_score":0.9999739,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2529221862","doi":"10.1186/s40425-016-0171-8","title":"Antitumor activity of nivolumab on hemodialysis after renal allograft rejection","year":2016,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"Ottawa Hospital","funders":"","keywords":"Medicine; Nivolumab; Hemodialysis; Ipilimumab; Transplantation; Immunosuppression; Internal medicine; Malignancy; Cancer; Intensive care medicine; Oncology; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.0154003820943477,"gpt":0.3142398967511063,"spread":0.2988395146567586,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0004452025,0.0001785991,0.0005121183,0.0002584498,0.00007946471,0.00001169785,0.0001107717,0.0001085473,0.000701312],"category_scores_gemma":[0.00002728804,0.0001103811,0.0006759212,0.0002025985,0.0001672869,0.0001531205,0.000007024224,0.0001355757,9.215186e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002789873,"about_ca_system_score_gemma":0.0002450109,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001459022,"about_ca_topic_score_gemma":0.00004712545,"domain_scores_codex":[0.9986412,0.00005104458,0.0005049908,0.0001854362,0.0003783343,0.0002390197],"domain_scores_gemma":[0.9986941,0.0000977685,0.0005688302,0.000278518,0.0003028569,0.00005792887],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.05013827,0.0001924785,0.003185688,0.0000417012,0.0008036257,0.000002449794,0.00008837605,0.00000250603,0.6707848,0.000005931955,0.0009697198,0.2737845],"study_design_scores_gemma":[0.01347486,0.002918681,0.08670757,0.001026809,0.0001797991,0.00004652415,0.0000188423,0.00001091057,0.8312846,0.0001237419,0.06401831,0.0001892868],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9908791,0.00393533,0.002056141,0.001758737,0.0007997385,0.0003743352,0.00005285866,0.00001418751,0.0001295328],"genre_scores_gemma":[0.9889188,0.007421188,0.0005050095,0.0003131049,0.000345352,0.00006292084,0.000001028606,0.00003792451,0.002394686],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2735952,"threshold_uncertainty_score":0.7678874,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W3015555708","doi":"10.1136/jitc-2019-000313","title":"Efficacy and safety of avelumab treatment in patients with metastatic Merkel cell carcinoma: experience from a global expanded access program","year":2020,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Polyomavirus and related diseases","field":"Medicine","cited_by":81,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false},"ca_institutions":"University of Alberta","funders":"Merck KGaA; Pfizer","keywords":"Avelumab; Merkel cell carcinoma; Medicine; Expanded access; Merkel cell polyomavirus; Progressive disease; Merkel cell; Internal medicine; Oncology; Clinical trial; Chemotherapy; Carcinoma; Immunotherapy; Cancer; Nivolumab","retraction":null,"screen_n_in":null,"score":{"opus":0.02488577820652711,"gpt":0.3496780509239403,"spread":0.3247922727174132,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.00002554317,0.0001386709,0.0004186504,0.00003310015,0.00004073892,0.00001546953,0.00008299463,0.0000336886,0.0000674274],"category_scores_gemma":[0.000007838375,0.00008479076,0.00009557723,0.0001352934,0.00008068627,0.00009968763,0.000009802489,0.00006584117,8.97295e-8],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0001187805,"about_ca_system_score_gemma":0.0002389984,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0007350325,"about_ca_topic_score_gemma":0.00001903092,"domain_scores_codex":[0.9991068,0.00002369553,0.0003682213,0.0001392108,0.0002090139,0.0001530628],"domain_scores_gemma":[0.999395,0.00002750549,0.0002724148,0.00009104361,0.00009064635,0.0001233781],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"observational","study_design_gemma":"observational","study_design_scores_codex":[0.0703687,0.002949678,0.6709992,0.0001333317,0.0008849754,0.00001668215,0.005244134,0.00008278395,0.002623544,0.000002476194,0.00004200052,0.2466525],"study_design_scores_gemma":[0.05449624,0.004970431,0.9316345,0.0002333242,0.0003154311,0.000002589743,0.0003034993,0.0001078754,0.007120462,0.0000156029,0.0006811219,0.0001188825],"study_design_candidate":"observational","study_design_consensus":"observational","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9844187,0.0141681,0.0000556853,0.000142877,0.00006014003,0.0009619427,0.000153008,0.000006027388,0.00003348087],"genre_scores_gemma":[0.9976805,0.001359362,0.0007279386,0.0001005611,0.00002677034,0.00006687373,0.000009935481,0.0000140993,0.00001398854],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.2606353,"threshold_uncertainty_score":0.3457667,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2997299711","doi":"10.1186/s40425-019-0816-5","title":"High expression of B7-H3 on stromal cells defines tumor and stromal compartments in epithelial ovarian cancer and is associated with limited immune activation","year":2019,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Cancer Immunotherapy and Biomarkers","field":"Medicine","cited_by":80,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Toronto General Hospital; Princess Margaret Cancer Centre; University of Toronto; University Health Network","funders":"Canadian Institutes of Health Research","keywords":"Stromal cell; Tumor microenvironment; Immune system; Cancer research; Immune checkpoint; Biology; Granzyme B; Ovarian cancer; CD8; Immunology; Cancer; Immunotherapy","retraction":null,"screen_n_in":null,"score":{"opus":0.01438185902002983,"gpt":0.2837279932218585,"spread":0.2693461342018287,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0002783832,0.0002309082,0.0006601507,0.0002226511,0.00007729325,0.00002437788,0.00008476347,0.0001024043,0.0002463124],"category_scores_gemma":[0.000009972999,0.000167321,0.0001134704,0.0001826492,0.0001035527,0.0001675226,0.00001202856,0.0002047747,1.475328e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002056431,"about_ca_system_score_gemma":0.0001729431,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008874718,"about_ca_topic_score_gemma":0.00006246819,"domain_scores_codex":[0.9985365,0.00005126317,0.0005863176,0.0002179969,0.0003555378,0.0002524247],"domain_scores_gemma":[0.9987116,0.0001201394,0.0007572761,0.0001626146,0.0001942708,0.00005409859],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.03721004,0.000276511,0.05423032,0.00009600734,0.0005520957,0.000002149975,0.0005303908,0.00006209496,0.8977163,0.00001059014,0.0001204977,0.009192994],"study_design_scores_gemma":[0.02254075,0.002715544,0.449759,0.002268154,0.00006669283,0.000009135624,0.0001556834,0.00006857521,0.5215901,0.00002879413,0.0006374461,0.0001600518],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9952332,0.002880326,0.00001898322,0.00056575,0.0003527541,0.0007374831,0.0001849754,0.000007790398,0.00001869274],"genre_scores_gemma":[0.9965279,0.002302065,0.0003604661,0.0003425483,0.00007737674,0.00004472038,0.00001366025,0.00004051429,0.0002908007],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.3955287,"threshold_uncertainty_score":0.6823152,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W4206536750","doi":"10.1136/jitc-2021-003289","title":"CD70 as an actionable immunotherapeutic target in recurrent glioblastoma and its microenvironment","year":2022,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"Immune cells in cancer","field":"Immunology and Microbiology","cited_by":79,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"Princess Margaret Cancer Centre; University of Toronto; McMaster University","funders":"Mitacs; Terry Fox Research Institute; McMaster University","keywords":"Glioblastoma; Tumor microenvironment; Immunotherapy; Medicine; Cancer research; Computer science; Computational biology; Internal medicine; Cancer; Biology; Tumor cells","retraction":null,"screen_n_in":null,"score":{"opus":0.01204532903169529,"gpt":0.294248444972102,"spread":0.2822031159404066,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":["insufficient_payload"],"consensus_categories":[],"category_scores_codex":[0.0006553803,0.0002357734,0.0004107758,0.0002610545,0.0005231371,0.00002166255,0.000384349,0.0001128199,0.007007999],"category_scores_gemma":[0.000008321494,0.0002117203,0.0001576155,0.0001545706,0.0001203242,0.0002168579,0.00007624811,0.0006674884,0.00000971506],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005880775,"about_ca_system_score_gemma":0.0002153966,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0000989322,"about_ca_topic_score_gemma":0.00002285128,"domain_scores_codex":[0.998287,0.0002508941,0.0006079155,0.0002865087,0.0001170643,0.0004506749],"domain_scores_gemma":[0.9991401,0.00007953627,0.0004554233,0.0002360058,0.00006528185,0.00002361157],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"not_applicable","study_design_scores_codex":[0.008539329,0.0004666659,0.0004890343,0.00003354509,0.0004709574,0.000003073068,0.001809656,0.0008850366,0.9182734,0.0001143926,0.0008160741,0.0680988],"study_design_scores_gemma":[0.006145448,0.003252113,0.001927809,0.00005918802,0.0000335291,0.0002899704,0.0008203085,0.00004440828,0.2769056,0.001031645,0.7091897,0.0003002637],"study_design_candidate":"bench_or_experimental","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.7700773,0.2254357,0.00003555586,0.0005868726,0.003206985,0.0005099368,0.00007926414,0.00001337279,0.00005492023],"genre_scores_gemma":[0.9599272,0.02971912,0.0002065561,0.0009219614,0.00009687438,0.0005798163,0.00002528617,0.00009919033,0.008423973],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.7083736,"threshold_uncertainty_score":0.9938997,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null},{"id":"W2221239533","doi":"10.1186/s40425-015-0099-4","title":"Designed ankyrin repeat proteins are effective targeting elements for chimeric antigen receptors","year":2015,"lang":"en","type":"article","venue":"Journal for ImmunoTherapy of Cancer","topic":"CAR-T cell therapy research","field":"Medicine","cited_by":79,"is_retracted":false,"has_abstract":true,"routes":{"ca_aff":true,"ca_fund":true,"ca_venue":false,"about_ca":false},"ca_institutions":"McMaster University; McMaster University Medical Centre","funders":"Terry Fox Foundation; Government of Ontario","keywords":"Chimeric antigen receptor; Antigen; Cytotoxic T cell; Degranulation; Ankyrin repeat; Tumor antigen; Antibody; Biology; Cancer research; Immunology; Cell biology; Receptor; Immunotherapy; Immune system; In vitro; Gene; Genetics","retraction":null,"screen_n_in":null,"score":{"opus":0.04065385021059447,"gpt":0.3816428080727803,"spread":0.3409889578621859,"validation_status":"score_only:v0-immature-baseline"},"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001877665,0.0002322034,0.0006150585,0.0002288844,0.000197838,0.00004258484,0.0002066288,0.0001098384,0.0007702549],"category_scores_gemma":[0.0002848801,0.0001851109,0.00040609,0.0002588154,0.00008313864,0.000149491,0.00001784187,0.0002851878,0.000002189278],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0006037886,"about_ca_system_score_gemma":0.0004583228,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00009797011,"about_ca_topic_score_gemma":0.00001189453,"domain_scores_codex":[0.9978775,0.0001281992,0.0006361029,0.0002582254,0.0005894487,0.0005105146],"domain_scores_gemma":[0.9977533,0.0001534677,0.0006384373,0.0002466671,0.001007284,0.0002008174],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"bench_or_experimental","study_design_gemma":"bench_or_experimental","study_design_scores_codex":[0.01631714,0.000207993,0.01548524,0.0001493663,0.001116926,0.00000387996,0.0011422,0.0000373054,0.7221398,0.000003823704,0.009799078,0.2335973],"study_design_scores_gemma":[0.02059955,0.006276421,0.006059723,0.0006185612,0.0001013195,0.00004337847,0.000820514,0.0002145112,0.554008,0.0003841367,0.4105369,0.0003369975],"study_design_candidate":"bench_or_experimental","study_design_consensus":"bench_or_experimental","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9611104,0.01891479,0.009198857,0.001205803,0.001596584,0.007626154,0.00005098226,0.00004468945,0.0002517658],"genre_scores_gemma":[0.7736264,0.02433199,0.1197806,0.002362241,0.009364468,0.009163243,0.0001409359,0.001123756,0.06010637],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.4007378,"threshold_uncertainty_score":0.843375,"prediction_status":"machine_predicted_unvalidated"},"labels":[],"label_agreement":null}]}